研究者詳細 - 山本　卓

論文 - 山本　卓

分割表示 >> ／全件表示 191 件中 1 - 191 件目

Appropriate Anthropometric Indices for Geriatric Nutritional Risk Index in Predicting Mortality in Older Japanese Patients: A Comparison of the Lorentz Formula and Body Mass Index. 査読

Kou Kitabayashi, Suguru Yamamoto, Ichiei Narita

The Tohoku journal of experimental medicine 262 ( 4 ) 221 - 228 2024年4月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

The Geriatric Nutritional Risk Index (GNRI) is a popular nutritional screening tool. However, the calculation of ideal body weight (IBW) differs among studies. We aimed to compare GNRI calculated using the Lorentz formula (LF) with a body mass index (BMI) and to investigate the cutoffs based on original or quartile criteria for the association with mortality in elderly patients in Japan. This retrospective study enrolled patients aged 65 and older in a long-term care hospital. The GNRI was calculated using two different IBW methods: the LF and a BMI of 22 kg/m2. We categorized GNRI results based on the original criteria or quartile criteria. Mortality outcomes were analyzed using the GNRI based on IBW (LF or BMI) and its classification (original criteria or quartile) through Cox proportional hazard regression. There were 262 participants, including 160 women, with a median age of 86. There was a notable difference between GNRI-BMI and GNRI-LF. The GNRI-LF original and quartile criteria did not show an association with mortality. A significant association with mortality was found between Q1 and Q4 in the GNRI-BMI quartile criteria (hazard ratio: 2.60; 95% confidence interval: 1.66-4.07, p < 0.01), but not the GNRI-BMI original criteria. The GNRI calculated using BMI with quartile criteria proved to be a reliable predictor of mortality for Japanese elderly inpatients. The calculation method of GNRI and the appropriate cutoff point should be considered based on the patient's background.

DOI： 10.1620/tjem.2024.J001

PubMed

researchmap

Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS. 査読国際誌

Suguru Yamamoto, Hanne Skou Jørgensen, Junhui Zhao, Angelo Karaboyas, Hirotaka Komaba, Marc Vervloet, Sandro Mazzaferro, Etienne Cavalier, Brian Bieber, Bruce Robinson, Pieter Evenepoel, Masafumi Fukagawa

Kidney international reports 9 ( 4 ) 863 - 876 2024年4月

Low muscle strength and physical function contribute to falls in hemodialysis patients, but not muscle mass. 査読

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Tsubasa Sugahara, Ichiei Narita

Clinical and experimental nephrology 28 ( 1 ) 67 - 74 2024年1月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Patients on hemodialysis (HD) have a higher incidence of fractures than the general population. Sarcopenia is frequently observed in patients on HD; however, the association of falls with sarcopenia and its diagnostic factors, including muscle mass, muscle strength, and physical function, are incompletely understood. METHODS: This prospective cohort study was conducted at a single center. Sarcopenia was assessed according to the 2019 Asian Working Group for Sarcopenia diagnostic criteria. Muscle mass was measured the bioelectrical impedance method. Grip strength was evaluated to assess muscle strength, while the Short Physical Performance Battery (SPPB) was used to assess physical function. Falls and their detailed information were surveyed every other week. RESULTS: This study analyzed 65 HD patients (median age, 74.5 [67.5-80.0] years; 33 women [49.2%]). Sarcopenia was diagnosed in 36 (55.4%) patients. During the 1-year observation period, 31 (47.7%) patients experienced accidental falls. The falls group had lower median grip strength than the non-falls group (14.7 [11.4-21.8] kg vs. 22.2 [17.9-27.6] kg; p < 0.001). The median SPPB score was also lower in the falls versus non-falls group (7.0 [5.0-11.0] vs. 11.0 [8.0-12.0]; p = 0.009). In adjusted multiple regression analysis, diagnostic factors, including grip strength (B = 0.96, p = 0.04, R2 = 0.19) and SPPB (B = 1.11, p = 0.006, R2 = 0.23), but not muscle mass, were independently associated with fall frequency. CONCLUSIONS: The frequency of falls in HD patients was related to muscle strength and physical function, but not muscle mass.

DOI： 10.1007/s10157-023-02403-4

PubMed

researchmap

Pruritus and protein-bound uremic toxins in patients undergoing hemodialysis: a cross-sectional study. 国際誌

Suguru Yamamoto, Takahiro Tanaka, Kentaro Omori, Isei Ei, Kaori Kikuchi, Ayano Konagai, Shin Goto, Nobutaka Kitamura, Ichiei Narita

Clinical kidney journal 17 ( 1 ) sfae007 2024年1月

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Patients undergoing hemodialysis frequently experience pruritus; its severity is associated with poor quality of life and mortality. Recent progress in hemodialysis treatment has improved the removal of small- and middle-molecular-weight molecules; however, the removal of protein-bound uremic toxins (PBUTs) remains difficult. It is possible that pruritus is associated with serum PBUTs in patients undergoing hemodialysis. METHODS: We conducted a multicenter cross-sectional study in patients undergoing hemodialysis (n = 135). The severity of pruritus was assessed using the 5D-itch scale and medication use. Serum PBUTs, including indoxyl sulfate, p-cresyl sulfate, indole acetic acid, phenyl sulfate, and hippuric acid, were measured using mass spectrometry; the PBUT score was calculated from these toxins using principal component analysis. Univariate and multiple regression analyses were performed to examine independent predictors of pruritus. RESULTS: Pruritus was reported by 62.2%, 21.5%, and 13.3%, 1.5% and 0.7% as 5 (not at all), 6-10, 11-15, 16-20, and 21-25 points, respectively. The PBUT score was higher in patients undergoing dialysis having pruritus than those without pruritus (0.201 [-0.021 to 0.424] vs -0.120 [-0.326 to 0.087]; P = 0.046). The PBUT score was shown to have an association with the presence of pruritus (coefficient 0.498[Formula: see text]0.225, odds ratio: 1.65 [1.06-2.56]; P = 0.027). CONCLUSION: Uremic pruritus was frequently found and associated with the PBUT score in patients undergoing hemodialysis. Further studies are required to clarify the impact of PBUTs on uremic pruritus and to explore therapeutic strategies in patients undergoing hemodialysis.

DOI： 10.1093/ckj/sfae007

PubMed

researchmap

Removal of α1-Microglobulin Using Post-Dilution Online Hemodiafiltration with Polymethylmethacrylate Membrane: An Open-Label, Single-Arm Study. 査読国際誌

Shiori Yoshida, Suguru Yamamoto, Daisuke Miyauchi, Ryohei Terashima, Atsushi Hashimoto, Haruna Miyazawa, Takahiro Tanaka, Masahiro Ishizawa, Mototsugu Tanaka, Yoshihiko Tomita, Ikuo Aoike, Shin Goto, Ichiei Narita

Blood purification 53 ( 2 ) 123 - 129 2024年

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: The removal of low- and medium-molecular-weight proteins has been improved with online hemodiafiltration (OL-HDF) and hemodialysis using high-flux membranes; however, the outcomes of patients with end-stage kidney disease (ESKD) undergoing dialysis treatment are still worse than in the general population. α1-Microglobulin (α1-m), with a molecular weight of 33,000 Da, may contribute to dialysis-related disorders and mortality. However, the removal is insufficient even with current OL-HDF using the polysulfone (PS) membrane, which is common in Japan. Polymethylmethacrylate (PMMA) membranes can remove medium- to high-molecular-weight proteins by adsorption. This study aimed to assess the efficacy of removing medium- to high-molecular-weight proteins, such as α1-m and β2-microglobulin (β2-m), through post-dilution OL-HDF with PMMA (Post-PMMA). The assessment was conducted in comparison to pre-dilution OL-HDF with PS (Pre-PS), using an open-label, single-arm study. METHODS: Seven patients with ESKD on Pre-PS underwent Post-PMMA with replacement volume of 30 mL/min (low flow) and 50 mL/min (high flow). Clearance and removal rates of α1-m, β2-m, small molecules, inflammatory cytokines, and albumin were measured at 60 and 240 min of treatment. RESULTS: Clearance rates of α1-m at 60 min were -2.8 ± 5.2 mL/min with Pre-PS, -0.4 ± 2.6 mL/min with Post-PMMA (low), and 0.6 ± 3.4 mL/min with Post-PMMA (high). The removal rate of α1-m was higher in Post-PMMA than that in Pre-HDF-PS (Post-PMMA [high] 17.7 ± 5.9%, Post-PMMA [low] 15.0 ± 5.6%, and Pre-PS 4.1 ± 5.5%). Adsorption clearance of β2-m was increased with Post-PMMA. Albumin leakage in Post-PMMA was not higher than that in Pre-PS. CONCLUSION: The removal rate of α1-m with Post-PMMA was higher than that with Pre-PS. The PMMA membrane adsorbed β2-m, suggesting the removal effect of medium- to high-molecular-weight proteins by the adsorption method. Since Post-PMMA effectively removes α1-m without excessive albumin leakage, it will be useful for patients with ESKD, especially those with a poor nutritional status.

DOI： 10.1159/000534459

PubMed

researchmap

Dynamic and static balance functions in hemodialysis patients and non-dialysis dependent CKD patients. 査読国際誌

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Ichiei Narita

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 27 ( 3 ) 412 - 418 2023年6月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) have a high risk of falls, whereas the impairment in balance function and their types in HD compared with non-dialysis dependent (ND) CKD have not been fully evaluated. METHODS: We conducted a cross-sectional study to assess the balance function in 91 ND-CKD and 65 HD patients. The participants underwent the timed up-and-go test (TUG) to assess dynamic balance and length of the center of pressure (CoP) with open eyes or closed eyes to evaluate static balance. RESULTS: TUG, length of CoP with open eyes, and length of CoP with closed eyes were longer in HD patients compared with those with ND-CKD. Multiple regression analysis showed that dialysis treatment independently affected TUG and length of CoP with open eyes. CONCLUSION: The dynamic and static balance functions are impaired in HD patients compared with that ND-CKD patients. This article is protected by copyright. All rights reserved.

DOI： 10.1111/1744-9987.13931

PubMed

researchmap

プロテオーム解析招待

羽深将人, 山本卓, 内木宏延, 山本格, 成田一衛

64 ( 8 ) 863 - 867 2022年12月

Macromolecular crowding and supersaturation protect hemodialysis patients from the onset of dialysis-related amyloidosis. 査読国際誌

Kichitaro Nakajima, Keiichi Yamaguchi, Masahiro Noji, César Aguirre, Kensuke Ikenaka, Hideki Mochizuki, Lianjie Zhou, Hirotsugu Ogi, Toru Ito, Ichiei Narita, Fumitake Gejyo, Hironobu Naiki, Suguru Yamamoto, Yuji Goto

Nature communications 13 ( 1 ) 5689 - 5689 2022年10月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Cold Spring Harbor Laboratory

Abstract

Dialysis-related amyloidosis (DRA), a serious complication among long-term hemodialysis patients, is caused by amyloid fibrils of β2-microglobulin (β2m). Although high serum β2m levels and a long dialysis vintage are the primary and secondary risk factors for the onset of DRA, respectively, patients with these do not always develop DRA, indicating that there are additional risk factors. To clarify these unknown factors, we investigated the effects of human sera on β2m amyloid fibril formation. Although sera markedly inhibited amyloid fibril formation, the inhibitory effects were weaker for sera collected from dialysis patients than for control sera. When sera collected before and after maintenance dialysis treatments were compared, the latter inhibited amyloid fibril formation more than the former. These results indicate that, although the inhibitory effects of sera were deteriorated in long-term dialysis patients, they were ameliorated by maintenance dialysis treatments in the short term. Maintenance dialysis decreases the body weight by 5% and consequently increases the concentrations of serum components. Among these components, we found that serum albumin prevented amyloid fibril formation based on macromolecular crowding effects, and that the decreased serum albumin concentration in dialysis patients is a tertiary risk factor for the onset of DRA. The model was constructed assuming accumulative effects of three risk factors and may be useful for predicting the onset of DRA. Furthermore, the model suggested the importance of monitoring temporary and accumulated risks to prevent the development of amyloidoses in general, which occurs based on supersaturation-limited amyloid fibril formation in a crowded milieu.

DOI： 10.1038/s41467-022-33247-3

PubMed

researchmap

Association of the nutritional risk index for Japanese hemodialysis with mortality and dietary nutritional intake in patients undergoing hemodialysis during long-term hospitalization. 査読

26 ( 12 ) 1200 - 1207 2022年8月

Relationship between Nutrition-Related Problems and Falls in Hemodialysis Patients: A Narrative Review. 査読国際誌

Nobuyuki Shirai, Tatsuro Inoue, Masato Ogawa, Masatsugu Okamura, Shinichiro Morishita, Yamamoto Suguru, Atsuhiro Tsubaki

Nutrients 14 ( 15 ) 3225 - 3225 2022年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：MDPI AG

Falls are a social problem that increase healthcare costs. Hemodialysis (HD) patients need to avoid falling because fractures increase their risk of death. Nutritional problems such as frailty, sarcopenia, undernutrition, protein-energy wasting (PEW), and cachexia may increase the risk of falls and fractures in patients with HD. This review aimed to summarize the impact of frailty, sarcopenia, undernutrition, PEW, and cachexia on falls in HD patients. The reported global incidence of falls in HD patients is 0.85–1.60 falls per patient per year. HD patients fall frequently, but few reports have investigated the relationship between nutrition-related problems and falls. Several studies reported that frailty and undernutrition increase the risk of falls in HD patients. Nutritional therapy may help to prevent falls in HD patients. HD patients’ falls are caused by nutritional problems such as iatrogenic and non-iatrogenic factors. Falls increase a person’s fear of falling, reducing physical activity, which then causes muscle weakness and further decreased physical activity; this cycle can cause multiple falls. Further research is necessary to clarify the relationships between falls and sarcopenia, cachexia, and PEW. Routine clinical assessments of nutrition-related problems are crucial to prevent falls in HD patients.

DOI： 10.3390/nu14153225

PubMed

researchmap

Magnesium intake by enteral formulation affects serum magnesium concentration in patients undergoing hemodialysis. 査読国際誌

Kou Kitabayashi, Suguru Yamamoto, Ichiei Narita

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Decreased serum magnesium levels are associated with mortality and fractures in patients with chronic kidney disease; however, there is no recommendation for Mg intake in these populations. This study used cross-sectional analysis to examine the association between Mg intake and serum Mg levels in patients undergoing hemodialysis. Sixty-one patients were included. The daily Mg intake was 185 mg (IQR: 151-203 mg), and serum Mg level was 2.4 mg/dL (IQR: 2.2-2.7 mg/dL). Multiple regression analysis showed that intake of enteral formulation by tube feeding was an independent factor associated with serum Mg level (B = 0.90 [95% confidence interval: 0.61-1.20], p < 0.01). These findings may aid in serum Mg level management through diet and enteral formulation in patients undergoing hemodialysis.

DOI： 10.1111/1744-9987.13760

PubMed

researchmap

Dysfunction in dynamic, but not static balance is associated with risk of accidental falls in hemodialysis patients: a prospective cohort study. 査読国際誌

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Ichiei Narita

BMC nephrology 23 ( 1 ) 237 - 237 2022年7月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Patients with chronic kidney disease undergoing hemodialysis (HD) have a high incidence of falls. Impairment of balance function is a risk factor for falls in the general elderly, and no report examining the association between balance dysfunction and fall incidence in HD patients exists. METHODS: This prospective cohort study was conducted at a single center. The timed-up-and-go test (TUG) as a dynamic balance function was performed and length of the center of pressure (CoP) as a static balance function was measured before and after the HD session at baseline. Data of the number and detailed information of accidental falls for 1 year were collected. Multiple regression analyses were performed to assess the relationships between the number of falls and balance function. RESULTS: Forty-three patients undergoing HD were enrolled in the study. During 1 year of observation, 24 (55.8%) patients experienced accidental falls. TUG time was longer, and CoP was shorter in the post-HD session than in the pre-HD session. Adjusted multiple regression analyses showed that the number of accidental falls was independently associated with TUG time in the pre-HD session (B 0.267, p < 0.001, R2 0.413) and that in the post-HD session (B 0.257, p < 0.001, R2 0.530), but not with CoP. CONCLUSIONS: Dynamic balance was associated with fall incidence in maintenance HD patients. The evaluation and intervention of dynamic balance function might reduce the risk of falls in HD patients. TRIAL REGISTRATION: This study was carried out with the approval of the Niigata Rinko Hospital Ethics Committee (approval number 2005-92) (Registered on December 11, 2019) and registered in The University Hospital Medical Information Network (registration number 000040618 ).

DOI： 10.1186/s12882-022-02877-6

PubMed

researchmap

Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study. 査読国際誌

Suguru Yamamoto, Brian A Bieber, Hirotaka Komaba, Norio Hanafusa, Hiroki Kitabayashi, Takanobu Nomura, Aleix Cases, Christian Combe, Ronald L Pisoni, Bruce M Robinson, Masafumi Fukagawa

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 32 ( 2 ) 243 - 250 2022年3月

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier BV

OBJECTIVES: Patients undergoing hemodialysis (HD) may have poor nutritional status and hyperphosphatemia. Nephrologists sometimes manage hyperphosphatemia by prescribing phosphate binders and/or recommending restriction of dietary phosphate including protein-rich foods; the later may, however, adversely affect nutritional status. DESIGN AND METHODS: The analysis includes 8805 HD patients on dialysis ≥ 120 days in 12 countries in Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 4 (2009-2011), from 248 facilities. The primary exposure variable was response to the following question: "For patients with serum albumin 3.0 g/dL and phosphate 6.0 mg/dL, do you recommend to (A) increase or (B) decrease/no change in dietary protein intake (DPI)?". The association between medical director's practice of recommending an increase in DPI and all-cause mortality was analyzed with Cox regression adjusted for potential confounders. Linear and logistic regressions were used to model the cross-sectional associations between DPI advice practice and intermediate markers of patient nutrition. RESULTS: Median follow-up was 1.6 years. In the case scenario, 91% of medical directors in North America had a practice of recommending DPI increase compared to 58% in Europe (range = 36%-83% across 7 countries) and 56% in Japan. The practice of advising DPI increase was weakly associated with lower mortality [HR (95% CI): 0.88 (0.76-1.02)]. The association tended to be stronger in patients with age 70+ years [HR (95% CI): 0.82 (0.69-0.97), P = .12 for interaction]. The practice of advising DPI increase was associated with 0.276 mg/dL higher serum creatinine levels (95% CI: 0.033-0.520) after adjustment for case mix. CONCLUSIONS: Medical director's practice of recommending an increase in DPI for HD patients with low albumin and high phosphate levels was associated with higher serum creatinine levels and potentially lower all-cause mortality. To recommend protein intake liberalization in parallel with phosphate management by physicians may be a critical practice for better nutritional status and outcomes in HD patients.

DOI： 10.1053/j.jrn.2021.02.007

PubMed

researchmap

Fear of falling and physical activity in hemodialysis patients: a pilot study 査読

Suguru Yamamoto

Renal Replacement Therapy 7 63 2021年11月

Comparison of muscle strength between hemodialysis patients and non-dialysis patients with chronic kidney disease. 査読

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Kanami Igarashi, Ichiei Narita

Journal of physical therapy science 33 ( 10 ) 742 - 747 2021年10月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

[Purpose] Muscle weakness in patients with chronic kidney disease is associated with several disease-related factors, and this study aimed to examine whether hemodialysis is one of risk factors for muscle weakness in patients with chronic kidney disease. [Participants and Methods] We conducted a cross-sectional study with 74 non-dialysis and 84 hemodialysis patients. Muscle strength evaluations were performed by measuring isometric knee extensor muscle strength and grip strength. Each evaluation item was compared between the hemodialysis and non-dialysis groups, and multiple regression analysis was performed to determine the factors associated with muscle strength. In addition, the correlation between lower-extremity muscle strength and grip strength was examined in each group. [Results] Isometric knee extensor muscle strength was significantly lower in the hemodialysis group than in the non-dialysis group. Grip strength was also significantly lower in the hemodialysis group than in the non-dialysis group. Hemodialysis was determined to be an independent risk factor associated with lower limb muscle strength as well as grip strength. The positive correlation between isometric knee extensor muscle strength and grip strength was almost the same in the groups. [Conclusion] Hemodialysis treatment was an independent risk factor for muscle weakness. Regular monitoring of grip strength may facilitate better management with physical therapy in hemodialysis patients.

DOI： 10.1589/jpts.33.742

PubMed

researchmap

Locomotive syndrome in hemodialysis patients and its association with quality of life-a cross-sectional study 査読

Suguru Yamamoto

Renal Replacement Therapy 7 36 2021年6月

Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. 査読国際誌

Suguru Yamamoto, Douglas S Fuller, Hirotaka Komaba, Takanobu Nomura, Ziad A Massy, Brian Bieber, Bruce Robinson, Ronald Pisoni, Masafumi Fukagawa

Clinical kidney journal 14 ( 4 ) 1236 - 1243 2021年4月

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Background</title>
Uremic toxins are associated with various chronic kidney disease-related comorbidities. Indoxyl sulfate (IS), a protein-bound uremic toxin, reacts with vasculature, accelerating atherosclerosis and/or vascular calcification in animal models. Few studies have examined the relationship of IS with clinical outcomes in a large cohort of hemodialysis (HD) patients.

</sec>
<sec>
<title>Methods</title>
We included 1170 HD patients from the Japan Dialysis Outcomes and Practice Patterns Study Phase 5 (2012–15). We evaluated the associations of serum total IS (tIS) levels with all-cause mortality and clinical outcomes including cardiovascular (CV)-, infectious- and malignancy-caused events using Cox regressions.

</sec>
<sec>
<title>Results</title>
The median (interquartile range) serum tIS level at baseline was 31.6 μg/mL (22.6–42.0). Serum tIS level was positively associated with dialysis vintage. Median follow-up was 2.8 years (range: 0.01–2.9). We observed 174 deaths (14.9%; crude rate, 0.06/year). Serum tIS level was positively associated with all-cause mortality [adjusted hazard ratio per 10 μg/mL higher, 1.16; 95% confidence interval (CI) 1.04–1.28]. Association with cause-specific death or hospitalization events, per 10 μg/mL higher serum tIS level, was 1.18 (95% CI 1.04–1.34) for infectious events, 1.08 (95% CI 0.97–1.20) for CV events and 1.02 (95% CI 0.87–1.21) for malignancy events after adjusting for covariates including several nutritional markers.

</sec>
<sec>
<title>Conclusions</title>
In a large cohort study of HD patients, serum tIS level was positively associated with all-cause mortality and infectious events.

</sec>

DOI： 10.1093/ckj/sfaa121

PubMed

researchmap

pH-Dependent Protein Binding Properties of Uremic Toxins In Vitro. 査読国際誌

Suguru Yamamoto, Kenichi Sasahara, Mio Domon, Keiichi Yamaguchi, Toru Ito, Shin Goto, Yuji Goto, Ichiei Narita

Toxins 13 ( 2 ) 116 - 116 2021年2月

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：MDPI AG

Protein-bound uremic toxins (PBUTs) are difficult to remove using conventional dialysis treatment owing to their high protein-binding affinity. As pH changes the conformation of proteins, it may be associated with the binding of uremic toxins. Albumin conformation at pH 2 to 13 was analyzed using circular dichroism. The protein binding behavior between indoxyl sulfate (IS) and albumin was examined using isothermal titration calorimetry. Albumin with IS, and serum with IS, p-cresyl sulfate, indole acetic acid or phenyl sulfate, as well as serum from hemodialysis patients, were adjusted pH of 3 to 11, and the concentration of the free PBUTs was measured using mass spectrometry. Albumin was unfolded at pH < 4 or >12, and weakened interaction with IS occurred at pH < 5 or >10. The concentration of free IS in the albumin solution was increased at pH 4.0 and pH 11.0. Addition of human serum to each toxin resulted in increased free forms at acidic and alkaline pH. The pH values of serums from patients undergoing hemodialysis adjusted to 3.4 and 11.3 resulted in increased concentrations of the free forms of PBUTs. In conclusion, acidic and alkaline pH conditions changed the albumin conformation and weakened the protein binding property of PBUTs in vitro.

DOI： 10.3390/toxins13020116

PubMed

researchmap

Inorganic polyphosphate potentiates lipopolysaccharide-induced macrophage inflammatory response. 査読国際誌

Toru Ito, Suguru Yamamoto, Keiichi Yamaguchi, Mami Sato, Yoshikatsu Kaneko, Shin Goto, Yuji Goto, Ichiei Narita

The Journal of biological chemistry 295 ( 12 ) 4014 - 4023 2020年3月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Inorganic polyphosphate (polyP) is a linear polymer of orthophosphate units that are linked by phosphoanhydride bonds and is involved in various pathophysiological processes. However, the role of polyP in immune cell dysfunction is not well-understood. In this study, using several biochemical and cell biology approaches, including cytokine assays, immunofluorescence microscopy, receptor-binding assays with quartz crystal microbalance, and dynamic light scanning, we investigated the effect of polyP on in vitro lipopolysaccharide (LPS)-induced macrophage inflammatory response. PolyP up-regulated LPS-induced production of the inflammatory cytokines, such as tumor necrosis factor α, interleukin-1β, and interleukin-6, in macrophages, and the effect was polyP dose- and chain length-dependent. However, orthophosphate did not exhibit this effect. PolyP enhanced the LPS-induced intracellular macrophage inflammatory signals. Affinity analysis revealed that polyP interacts with LPS, inducing formation of small micelles, and the polyP-LPS complex enhanced the binding affinity of LPS to Toll-like receptor 4 (TLR4) on macrophages. These results suggest that inorganic polyP plays a critical role in promoting inflammatory response by enhancing the interaction between LPS and TLR4 in macrophages.

DOI： 10.1074/jbc.RA119.011763

PubMed

researchmap

Adsorption of Protein-Bound Uremic Toxins Using Activated Carbon through Direct Hemoperfusion in vitro 査読

Suguru Yamamoto, Toru Ito, Mami Sato, Shin Goto, Junichiro J. Kazama, Fumitake Gejyo, Ichiei Narita

Blood Purification 48 ( 3 ) 215 - 222 2019年

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS) 査読

Yamamoto Suguru, Karaboyas Angelo, Komaba Hirotaka, Taniguchi Masatomo, Nomura Takanobu, Bieber Brian A, De Sequera Patricia, Christensson Anders, Pisoni Ronald L, Robinson Bruce M, Fukagawa Masafumi

BMC NEPHROLOGY 19 ( 1 ) 2018年10月

Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016. 査読

Yamamoto S

Clinical and experimental nephrology 23 ( 2 ) 1 - 7 2018年6月

Indoxyl Sulfate Promotes Macrophage IL-1β Production by Activating Aryl Hydrocarbon Receptor/NF-κ/MAPK Cascades, but the NLRP3 inflammasome Was Not Activated. 査読

Wakamatsu T, Yamamoto S, Ito T, Sato Y, Matsuo K, Takahashi Y, Kaneko Y, Goto S, Kazama JJ, Gejyo F, Narita I

Toxins 10 ( 3 ) 2018年3月

Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis 査読

Suguru Yamamoto, Mami Sato, Yoko Sato, Takuya Wakamatsu, Yoshimitsu Takahashi, Akira Iguchi, Kentaro Omori, Yasushi Suzuki, Isei Ei, Yoshikatsu Kaneko, Shin Goto, Junichiro J. Kazama, Fumitake Gejyo, Ichiei Narita

Artificial Organs 42 ( 1 ) 88 - 93 2018年1月

Uremic Toxicity and Bone in CKD 査読

Suguru Yamamoto, Masafumi Fukagawa

JOURNAL OF NEPHROLOGY 30 ( 5 ) 623 - 627 2017年10月

Direct hemoperfusion with β<inf>2</inf>-microglobulin adsorption column for patients with end-stage kidney disease

Suguru Yamamoto, Junichro J. Kazama

Hemoperfusion, Plasmaperfusion and Other Clinical Uses of General, Biospecific, Immuno and Leucocyte Adsorbents 4 285 - 296 2017年4月

Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease. 査読

Wakamatsu T, Yamamoto S, Kamimura K, Nakatsue T, Iino N, Iguchi S, Kaneko Y, Goto S, Kazama JJ, Narita I

CEN case reports 5 ( 2 ) 125 - 130 2016年11月

The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis 査読

Suguru Yamamoto, Ichiei Narita, Kazuhiko Kotani

CLINICA CHIMICA ACTA 457 117 - 122 2016年6月

Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype 査読

Suguru Yamamoto, Jiayong Zhong, Patricia G. Yancey, Yiqin Zuo, MacRae F. Linton, Sergio Fazio, Haichun Yang, Ichiei Narita, Valentina Kon

ATHEROSCLEROSIS 242 ( 1 ) 56 - 64 2015年9月

Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients 査読

Suguru Yamamoto, Junichiro J. Kazama, Kentaro Omori, Koji Matsuo, Yoshimitsu Takahashi, Kazuko Kawamura, Takayuki Matsuto, Hiroshi Watanabe, Toru Maruyama, Ichiei Narita

SCIENTIFIC REPORTS 5 14381 2015年9月

Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate 査読

Koji Matsuo, Suguru Yamamoto, Takuya Wakamatsu, Yoshimitsu Takahashi, Kazuko Kawamura, Yoshikatsu Kaneko, Shin Goto, Junichiro J. Kazama, Ichiei Narita

TOXINS 7 ( 8 ) 3155 - 3166 2015年8月

Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care 査読

Toshiki Doi, Suguru Yamamoto, Takatoshi Morinaga, Ken-ei Sada, Noriaki Kurita, Yoshihiro Onishi

PLOS ONE 10 ( 6 ) e0129180 2015年6月

Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients 査読

Suguru Yamamoto, Ryo Kido, Yoshihiro Onishi, Shingo Fukuma, Tadao Akizawa, Masafumi Fukagawa, Junichiro J. Kazama, Ichiei Narita, Shunichi Fukuhara

PLOS ONE 10 ( 4 ) e0122691 2015年4月

Chronic kidney disease induced dysfunction of high density lipoprotein 査読

Suguru Yamamoto, Valentina Kon

CLINICAL AND EXPERIMENTAL NEPHROLOGY 18 ( 2 ) 251 - 254 2014年4月

Autophagy: a two-edged sword in diabetes mellitus. 査読

Yamamoto S, Kazama JJ, Fukagawa M

The Biochemical journal 456 ( 3 ) e1 - 3 2013年12月

Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis 査読

Suguru Yamamoto, Patricia G. Yancey, Alp Ikizler, W. Gray Jerome, Ryohei Kaseda, Brian Cox, Aihua Bian, Ayumi Shintani, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Valentina Kon

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 60 ( 23 ) 2372 - 2379 2012年12月

β2-Microglobulin 査読

Suguru Yamamoto, Junichiro James Kazama, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo

Uremic Toxins 249 - 258 2012年9月

Macrophage Polarization by Angiotensin II-Type 1 Receptor Aggravates Renal Injury-Acceleration of Atherosclerosis 査読

Suguru Yamamoto, Patricia G. Yancey, Yiqin Zuo, Li-Jun Ma, Ryohei Kaseda, Agnes B. Fogo, Iekuni Ichikawa, MacRae F. Linton, Sergio Fazio, Valentina Kon

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 31 ( 12 ) 2856 - U277 2011年12月

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice 査読

Suguru Yamamoto, Yiqin Zuo, Ji Ma, Patricia G. Yancey, Tracy E. Hunley, Masaru Motojima, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Iekuni Ichikawa, Valentina Kon

NEPHROLOGY DIALYSIS TRANSPLANTATION 26 ( 8 ) 2491 - 2497 2011年8月

Recent progress in understanding dialysis-related amyloidosis 査読

Suguru Yamamoto, Junichiro James Kazama, Ichiei Narita, Hironobu Naiki, Fumitake Gejyo

BONE 45 S39 - S42 2009年7月

Mechanisms for increased cardiovascular disease in chronic kidney dysfunction 査読

Suguru Yamamoto, Valentina Kon

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION 18 ( 3 ) 181 - 188 2009年5月

Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders 査読

S. Yamamoto, J. J. Kazama, H. Maruyama, S. Nishi, I. Narita, F. Gejyo

CLINICAL NEPHROLOGY 70 ( 6 ) 496 - 502 2008年12月

Historical background and clinical treatment of dialysis-related amyloidosis. 査読

Yamamoto S, Gejyo F

Biochimica et biophysica acta 1753 ( 1 ) 4 - 10 2005年11月

Kinetic analysis of the polymerization and depolymerization of beta(2)-microglobulin-related amyloid fibrils in vitro. 査読

Yamamoto S, Hasegawa K, Yamaguchi I, Goto Y, Gejyo F, Naiki H

Biochimica et biophysica acta 1753 ( 1 ) 34 - 43 2005年11月

Low concentrations of sodium dodecyl sulfate induce the extension of beta(2)-microglobulin-related amyloid fibrils at a neutral pH 査読

S Yamamoto, K Hasegawa, Yamaguchi, I, S Tsutsumi, J Kardos, Y Goto, F Gejyo, H Naiki

BIOCHEMISTRY 43 ( 34 ) 11075 - 11082 2004年8月

Glycosaminoglycans enhance the trifluoroethanol-induced extensionof beta(2)-microglobulin-related amyloid fibrils at a neutral pH 査読

S Yamamoto, Yamaguchi, I, K Hasegawa, S Tsutsumi, Y Goto, F Gejyo, H Naiki

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 15 ( 1 ) 126 - 133 2004年1月

High peritoneal clearance of small molecules did not provide low serum beta(2)-microglobulin concentrations in peritoneal dialysis patients 査読

S Yamamoto, A Kasai, H Shimada

PERITONEAL DIALYSIS INTERNATIONAL 23 S34 - S36 2003年

Shared T-Cell Receptor Repertoire in the Tonsils of Patients with Immunoglobulin A Nephropathy

Kazunori Satokata, Shin Goto, Hiroki Yamaguchi, Hirofumi Watanabe, Nao Takahashi, Koichi Higashi, Suguru Yamamoto, Yoshikatsu Kaneko, Arata Horii, Ken Kurokawa, Ichiei Narita

Kidney360 2026年2月

Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy

Yuto Tanno, Naoki Kondo, Satoshi Ito, Yoko Wada, Takeshi Kuroda, Eriko Hasegawa, Daisuke Kobayashi, Suguru Yamamoto

BMC Rheumatology 2026年2月

Association Between the Fatigue Assessment Scale and Clinical Indices in Patients With Systemic Lupus Erythematosus

Kaho Sato, Ayako Wakamatsu, Daisuke Kobayashi, Hiroe Sato, Suguru Yamamoto, Yoshikatsu Kaneko

International Journal of Rheumatic Diseases 2026年2月

Assessment and treatment of metabolic acidosis in CKD: a registry-based study

Mai Tanaka, Michihiro Hosojima, Hideyuki Kabasawa, Shin Goto, Seiji Itano, Seiji Kishi, Hajime Nagasu, Naoki Kashihara, Suguru Yamamoto

Scientific Reports 16 ( 1 ) 2026年1月

Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment.

Hiroe Sato, Naoki Kondo, Tomoya Watarai, Eriko Hasegawa, Ayako Wakamatsu, Yukiko Nozawa, Daisuke Kobayashi, Takeshi Kuroda, Suguru Yamamoto

Journal of bone and mineral metabolism 2026年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: To determine the incidence and risk factors of fragility fractures and atypical femoral fracture (AFF)-related events in patients with systemic lupus erythematosus (SLE) receiving long-term glucocorticoid (GC) therapy. MATERIALS AND METHODS: A retrospective analysis was conducted of 170 SLE patients followed from 2016 to 2023. Data on GC use, bisphosphonate (BP) therapy, bone-related events, and clinical characteristics were collected. Risk factors for fragility fractures and AFF-related events, including localized periosteal thickening (LPT), were analyzed using multivariate logistic regression. RESULTS: Although the median daily dose of prednisolone decreased over time, 82.9% of patients still met the criteria for pharmacologic intervention for GC-induced osteoporosis in 2023, and most continued to receive > 5 mg/day of GC. The median duration of BP therapy was 10.4 years, with 69 patients maintaining BP treatment throughout the observation period (median, 12.5 years). Fragility fractures and AFF-related events occurred in 7.6% and 5.8% of patients, respectively. Fragility fractures were independently associated with SLE flares and infection-related hospitalizations, whereas AFF-related events were significantly associated with prolonged BP use. CONCLUSION: Despite a gradual reduction in GC dosage, many patients with longstanding SLE remain at elevated risk for fractures. The comparable frequencies of fragility fractures and AFF-related events highlight the clinical relevance of both complications. The prevention of SLE flares and infections may contribute to lowering the risk of fragility fractures. In addition, careful monitoring for AFF/LPT is warranted in patients receiving long-term BP and GC therapy.

DOI： 10.1007/s00774-025-01683-y

PubMed

researchmap

Effect of Romosozumab on Localized Periosteal Thickening: A Precursor to Atypical Femoral Fractures.

Hiroe Sato, Naoki Kondo, Eriko Hasegawa, Ayako Wakamatsu, Yukiko Nozawa, Daisuke Kobayashi, Junichiro James Kazama, Takeshi Kuroda, Naoto Endo, Suguru Yamamoto

The Tohoku journal of experimental medicine 2025年12月

Associations of calcium and magnesium intakes and their intake ratio with albuminuria in middle-aged and older adults. 国際誌

Keiko Kabasawa, Michihiro Hosojima, Kazutoshi Nakamura, Ribeka Takachi, Norie Sawada, Shoichiro Tsugane, Junta Tanaka, Suguru Yamamoto, Yumi Ito

PloS one 20 ( 11 ) e0335412 2025年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Calcium and magnesium both work together and against each other by sharing homeostatic regulatory systems in the kidneys. Previous studies suggested that these minerals and their intake ratio were associated with chronic health conditions such as cardiovascular disease. Our objective was to investigate the association of calcium and magnesium intake and their intake ratio with albuminuria. This cross-sectional study analyzed data from a Japanese community-based cohort comprising 6,849 individuals aged ≥40 years (mean age 68.8 years, 51.3% women). Energy-adjusted dietary intake of calcium and magnesium and the calcium-to-magnesium intake ratio were derived from a validated food frequency questionnaire. The outcome was spot urinary albumin-to-creatinine ratio (ACR, mg/g). Linear and logistic regression analyses were performed with adjustments for potential confounders. The analytic population had 1.65 and 73.5 mL/min/1.73 m2 as median intake ratio and estimated glomerular filtration rate, respectively. In multivariable linear regression analysis, lower intakes of calcium and magnesium were associated with the log-transformed ACR but, after mutual adjustment, only calcium intake was independently associated with the ACR (regression coefficient -0.084; 95%CI, -0.149, -0.019). A lower intake ratio was associated with the log-transformed ACR (regression coefficient, -0.085; 95%CI, -0.150, -0.021). These associations were evident overall and in male participants. Although magnesium intake was associated with albuminuria only before accounting for calcium intake, calcium intake and calcium-to-magnesium intake ratio demonstrated robust associations. Our findings support that the importance of calcium intake and its balancing with magnesium might extend to kidney health, especially albuminuria.

DOI： 10.1371/journal.pone.0335412

PubMed

researchmap

Megalin-Mediated Direct and Indirect Pathways for the Development of Contrast-Induced Proximal Tubule Epithelial Cell Injury. 国際誌

Sawako Goto, Michihiro Hosojima, Hideyuki Kabasawa, Kazuya Takemoto, Hiroyuki Aoki, Koichi Komochi, Ryota Kobayashi, Nanako Sugita, Taeko Endo, Shoji Kuwahara, Takahiro Tanaka, Ryohei Kaseda, Satoru Nagatoishi, Yutaka Yoshida, Ichiei Narita, Suguru Yamamoto, Kouhei Tsumoto, Yoshiaki Hirayama, Akihiko Saito

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 39 ( 20 ) e71136 2025年10月

Comprehensive Bibliometric Analysis of Uremic Toxin Research 国際誌

Marsuki Hardjo, Takuya Wakamatsu, Kazuki Watanabe, Shoko Yamazaki, Suguru Yamamoto

Toxins 17 ( 11 ) 2025年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

Uremic toxins accumulate as kidney disease progresses, contributing to diverse systemic disorders. Despite numerous studies, no comprehensive mapping has been performed. In this study, keywords related to uremic toxins were quantitatively analyzed using bibliometric methods to clarify research trends, key molecules, and unresolved challenges. Literature and molecular data on uremic toxins and chronic kidney disease were retrieved from the Web of Science and the European Uremic Toxin Work Group (EUTox) databases. Network, citation burst, and keyword frequency analyses were performed using KeyWords Plus. In total, 3302 articles were identified, showing an increasing trend. Citation burst analysis revealed a growing interest in gut microbiota-related topics (burst strength = 15.21), whereas keyword frequency analysis indicated that indoxyl sulfate (566 articles) and p-cresyl sulfate (537 articles) were the most studied toxins. Toxins such as trimethylamine-N-oxide have gained attention over the past 5 years. Analysis of the EUTox database identified 24 protein-bound uremic toxins; among the 94 toxins with unreported clinical toxicity, 15 molecules, including osteocalcin and quinolinic acid, were investigated in <5 studies. These findings suggest that the gut microbiota and related uremic toxins are current research focuses; however, further investigation of underreported uremic toxins is required to define their clinical significance.

DOI： 10.3390/toxins17110537

PubMed

researchmap

Species-specific outcomes and role of infectious disease consultation in peritoneal dialysis infections caused by nontuberculous mycobacteria: A 10-year retrospective analysis. 国際誌

Ikumi Yamagishi, Yuuki Bamba, Naoto Kanno, Masahiro Ui, Hayato Tsuruma, Mariko Hakamata, Hideyuki Ogata, Satoshi Shibata, Koji Matsuo, Nobumasa Aoki, Kazuko Kawamura, Yasuyoshi Ohshima, Satoshi Watanabe, Hiroshi Moro, Toshiyuki Koya, Shin Goto, Suguru Yamamoto, Toshiaki Kikuchi

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 8968608251389780 - 8968608251389780 2025年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

BackgroundInfections can make it difficult to continue peritoneal dialysis (PD). Nontuberculous mycobacteria-associated PD (NTM-PD) infections, while rare, frequently pose a treatment challenge due to their intractable nature and the lack of established therapeutic guidelines. As a result, we aimed to investigate the clinical characteristics of NTM infections in patients undergoing PD.MethodsWe retrospectively examined consecutive patients with NTM-PD infections from 2012 to 2022. The cases were identified through microbiological records. The primary outcomes were all-cause mortality and transition to hemodialysis. Secondary outcomes included treatment duration and antimicrobial regimens. Outcomes were compared across different NTM species and between cases with and without infectious disease (ID) consultation.ResultsAmong 177 patients undergoing PD, we identified 22 NTM infections in 20 patients. The predominant species were M. chelonae (36%), M. fortuitum (36%), and M. abscessus (23%). Twelve patients were transitioned to hemodialysis, with no mortality. All M. abscessus infections (n = 5) required transition to hemodialysis, compared to 46% in other species. ID consultation (n = 15) was linked to more frequent antimicrobial susceptibility testing (60% vs. 0%, p < .05), longer treatment duration (5.7 vs. 1.2 months, p < .05), and increased use of combination therapies (100% vs. 43%, p < .05). However, ID consultation did not affect the frequency of transition to hemodialysis.ConclusionEarly identification of NTM species and timely ID consultation can help optimize management strategies for these challenging infections.

DOI： 10.1177/08968608251389780

PubMed

researchmap

Estimating the impact of pill burden on health utilities in hemodialysis therapy. 国際誌

Hiroo Shimoda, Masatomo Taniguchi, Suguru Yamamoto, Ataru Igarashi, Shin Tokunaga, Keigo Hanada, Naoki Tashiro, Tatsunori Murata, Shinji Asada

Scientific reports 15 ( 1 ) 35315 - 35315 2025年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Patients undergoing hemodialysis often require numerous medications because of comorbidities including hyperphosphatemia, diabetes, and anemia, coupled with water restrictions. Reducing pill burden may alleviate psychological stress and improve quality of life (QOL). However, standardized instruments such as the EuroQOL 5 Dimensions inadequately measure these effects. We investigated the impact of pill burden on utility scores using a vignette-based time trade-off (TTO) method. Members of the general population were interviewed in person using vignettes representing seven health states with varying daily pill burdens (2, 3, 6, 9, 12, 24, and 36 tablets) in the context of hemodialysis patients, including disease characteristics, symptoms, and daily life restriction. Utility scores were evaluated using the TTO method and the impact of pill burden on QOL was estimated. The mean age (44.5 years) and sex distribution (50.5% male) of the 107 participants closely matched the general population of Japan. Utility scores decreased with higher pill burdens, ranging from 0.373 (0.579) [mean (standard deviation)] for 2 tablets/day to 0.239 (0.568) for 36 tablets/day. Compared with 2 tablets/day, the utility score for 6 tablets/day was significantly lower [mean (standard deviation) difference: 0.046 (0.223), P = 0.034, paired t-test)], with the difference showing a more significant as the number of tablets increased. Subgroup analyses by sex and age showed consistent trends with no significant differences between groups. A higher pill burden was associated with lower utility scores, highlighting its negative impact on QOL in patients undergoing hemodialysis. Reducing pill burden may improve QOL and address challenges related to water restrictions.

DOI： 10.1038/s41598-025-19346-3

PubMed

researchmap

その他リンク： https://www.nature.com/articles/s41598-025-19346-3

Dual Renal and Cardiac Phenotypes Associated with Rare Variants Inherited from Both Parents.

Ryo Aida, Hirofumi Watanabe, Takamitsu Shiiya, Chihiro Sakurazawa, Tadashi Otsuka, Shin Goto, Suguru Yamamoto

Internal medicine (Tokyo, Japan) 2025年10月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

We herein report a woman with autosomal dominant Alport syndrome (ADAS) with a family history of left ventricular noncompaction cardiomyopathy (LVNC). Exome sequencing identified a rare heterozygous variant in COL4A4, NM_000092.5: c.2510G>C (p.G837A), and a novel heterozygous variant in ACTC1, NM_005159.5: c.922T>C (p.Y308H), as causes of ADAS and LVNC, respectively. The cardiac phenotype was presumed to have been inherited paternally, whereas the renal phenotype was assumed to be maternally inherited. These two variants independently contributed to clinical phenotypes. This case highlights the clinical significance of comprehensive genetic testing for facilitating the precise diagnosis of rare and complex hereditary disorders.

DOI： 10.2169/internalmedicine.6003-25

PubMed

researchmap

Impact of upacicalcet on bone metabolism in hemodialysis patients with secondary hyperparathyroidism: a post-hoc analysis. 国際誌

Suguru Yamamoto, Shinji Yoneda, Hisami Yasuzawa, Junichiro James Kazama, Ichiei Narita

JBMR plus 9 ( 10 ) ziaf139 2025年10月

担当区分：筆頭著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Secondary hyperparathyroidism (SHPT) is a complication prevalent among patients undergoing hemodialysis (HD). Upacicalcet, a novel intravenous calcimimetic agent, has demonstrated efficacy in improving bone turnover by suppressing PTH production. However, the influence of baseline bone metabolism on the efficacy of calcimimetics remains unclear. Therefore, we aimed to evaluate the efficacy of upacicalcet on PTH suppression and changes in bone turnover based on bone-specific alkaline phosphatase (BAP) levels. This study involved a post-hoc analysis of data from a phase 3, placebo-controlled, double-blind trial evaluating the effect of upacicalcet in HD patients with SHPT. Patients were categorized into 3 groups based on tertiles of baseline serum BAP levels. Key biomarkers, including serum levels of intact PTH (iPTH), BAP, tartrate-resistant acid phosphatase-5b (TRACP-5b), and BAP/TRACP-5b ratio, were measured. Percentage changes from baseline in these parameters were assessed using a mixed-effects model for repeated measures. Additionally, cases of increased serum BAP levels following upacicalcet administration were investigated. A total of 103 HD patients with SHPT treated with upacicalcet were included in the analysis. Patients were categorized into low BAP (<12.8 μg/L), medium BAP (12.8-18.8 μg/L), and high BAP (>18.8 μg/L) groups. After 24 wk of upacicalcet intervention, iPTH levels decreased across all baseline BAP groups. Serum BAP and TRACP-5b levels decreased, whereas the BAP/TRACP-5b ratio increased across all groups. However, 26 (27.4%) patients exhibited increased BAP levels at week 24 relative to the levels at baseline despite the significant reduction in PTH levels. Upacicalcet treatment reduced PTH levels in HD patients with SHPT, regardless of baseline BAP levels. The concurrent increase in the BAP/TRACP-5b ratio with upacicalcet suggests that this agent may exert direct effects on bone metabolism, in addition to its role in suppressing parathyroid activity.

DOI： 10.1093/jbmrpl/ziaf139

PubMed

researchmap

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

David Kavanagh, Andrew S Bomback, Marina Vivarelli, Carla M Nester, Giuseppe Remuzzi, Ming-Hui Zhao, Edwin K S Wong, Yaqin Wang, Induja Krishnan, Imelda Schuhmann, Angelo J Trapani, Nicholas J A Webb, Matthias Meier, Rubeen K Israni, Richard J H Smith, Alejandra Ines Espinosa, Rita Marcela Fortunato, Magali Freijo Freijo, Nadia Fretes, Pablo Miguel Raffaele, Gianna Mastroianni Kirsztajn, Juliana Mansur Siliano, Laila Almeida Viana, Dervla Connaughton, Susan Huang, Faisal Rehman, Pavel Roshanav, Matthew A. Weir, Dong-Yuan Chang, Pei Chen, Bixia Gao, Ying Tan, Li Yang, Xiao-Juan Yu, Xin Zhang, Ming-Hui Zhao, Chuan-Ming Hao, Ling-Yun Lai, Shao-Jun Liu, Eva Jancova, Vladimir Tesar, Anne Blanchard, Sophie Chauvet, Nathalie Chavarot, Roxane Gaisset, François Provôt, Myriam Dao, Hamza Sakhi, Aude Servais, Julia Weinmann-Menke, Ute Eisenberger, Anja Gäckler, Benjamin Wilde, Anne Dieterle, Michael Wiesener, Tobias Huber, Malte Andreas Kluger, Eleftheria-Kleio Dermitzaki, Charikleia Gakiopoulou, Konstantinos Stylianou, Narayan Prasad, Dharmendra Singh Bhadauria, Dinesh Khullar, Soumita Bagchi, Naomi Ben-Dor, Valeria Morduhovich, Benaya Rozen-Zvi, Yael Borovitz, Daniel Landau, Camillo Carrara, Erica Daina, Amantia Imeraj, Maddalena Marasà, Piero Luigi Ruggenenti, Giuseppe Remuzzi, Luca Antonucci, Marcello Chinali, Antonio Gargiulo, Marina Vivarelli, Federica Zotta, Sosuke Fukui, Hangsoo Kim, Masashi Mizuno, Yasuhiro Suzuki, Shin Goto, Michihiro Hosojima, Hideyuki Kabasawa, Yoshikatsu Kaneko, Ryohie Kaseda, Ichiei Narita Narita, Tadashi Otsuka, Hirofumi Watanabe, Suguru Yamamoto, Motoki Matsuki, Naoki Nagakawa, Wataru Ohwada, Arata Osanami, Hidemichi Kouzu, Tomohisa Yamashita, Toshiyuki Yano, Hanneke Bouwsma, Aiko Popke Jan de Vries, Soufiane Meziyerh, Wouter Moest, Dennis A.J. Van den Broek, Y.K. Onno Teng, Teresa Cavero Escribano, Wenceslao Adrian Aguilera Morales, Francisco Jose de la Prada Alvarez, Fabiola Alonso Garcia, Mercedes Salgueira Lazo, Katarina Benackova, Uyen Huynh-Do, Laila-Yasmin Mani, Sibylle Tschumi, Asil Demirezen, Özant Helvaci, Betul Ogut, Saliha Yildirim, David Kavanagh, Edwin K.S. Wong, Tom Cairns, Stephen Paul McAdoo, Liz Lightstone, Nicholas Medjeral-Thomas, Matthew Pickering, Wooin Ahn, Gerald B. Appel, Andrew S. Bomback, Pietro Canetta, Elizabeth Hendren, Allyson Medina, Mariela Navarro-Torress, Jai Radhakrishnan, Jennifer Jetton, Christina Michels, Carla M. Nester, Richard J.H. Smith, James Alan Tumlin

The Lancet 406 ( 10512 ) 1587 - 1598 2025年10月

リチウム長期内服後尿細管の構造変化を伴わずにアクアポリン2の発現低下がみられた腎性尿崩症の一例

鈴木優也, 渡辺博文, 大塚忠司, 蒲澤秀門, 細島康宏, 忰田亮平, 後藤眞, 山本卓

日本腎臓学会誌 67 ( 6-E ) 789 - 789 2025年9月

二次性高血圧症の原因としてのレニン産生卵巣腫瘍

鈴木魁也, 工藤梨沙, 早福あやか, 谷地田希, 南川高廣, 渡辺博文, 忰田亮平, 山本卓, 吉原弘祐

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 72回 133 - 133 2025年9月

MPO-ANCA関連半月体形成性糸球体腎炎にC3腎症様変化を合併した一例

桜沢千尋, 逸見太郎, 渡辺博文, 大塚忠司, 蒲澤秀門, 細島康宏, 伊藤由美, 後藤眞, 山本卓

日本腎臓学会誌 67 ( 6-E ) 785 - 785 2025年9月

Direct Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-Related Amyloidosis. 査読国際誌

Shoko Yamazaki, Daisuke Miyauchi, Atsushi Hashimoto, Takahiro Tanaka, Mototsugu Tanaka, Hisaki Shimada, Yuji Ishii, Koji Matsuo, Akio Kasai, Yutaka Koda, Kokichi Saito, Junichi Hoshino, Shinichi Nishi, Suguru Yamamoto

Blood purification 54 ( 11 ) 1 - 10 2025年8月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：S. Karger AG

IntroductionDialysis-related amyloidosis (DRA) is a serious complication in patients undergoing long-term dialysis that leads to conditions such as carpal tunnel syndrome and destructive spondyloarthropathy. Improved removal of the precursor protein β2-microglobulin (β2-m) is considered an effective treatment strategy for DRA. Polymethylmethacrylate (PMMA) membranes have the capacity to adsorb β2-m in dialysis filters, suggesting that direct hemoperfusion with PMMA in addition to standard dialysis may enhance β2-m removal.MethodsThis prospective cohort study included 10 patients undergoing hemodialysis, who were diagnosed with DRA. The participants were treated with dialysis filter alone during Visit 1, both standard dialysis filter and PMMA cartridges (FT-75, volume 75 cm³) during Visits 2–4, and FT-145 PMMA cartridges (volume 145 cm³) during Visits 5–7. The removal rates and clearances of β2-m were quantified. We also assessed the removal of α1-microglobulin (α1-m), matrix metalloproteinase-3 (MMP-3), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α), which may be associated with DRA symptoms. ResultsPMMA cartridge had increased β2-m removal rates compared to dialysis filter alone for treatment duration of 240 min. Similarly, the removal rates of α1-m and MMP-3 were higher with PMMA cartridges than with dialysis filter alone. β2-m, α1-m, and MMP-3 clearance improved with the addition of PMMA cartridges, depending on the cartridge size. The removal rates of IL-6 and TNF-α were higher with PMMA cartridges than with dialysis filter alone at 30 min, but not at 240 min .ConclusionDirect hemoperfusion with PMMA is an effective method for removing β2-m in hemodialysis patients with DRA. Beneficial effects were also observed for the removal of α1-m and MMP-3. Further research is required to evaluate the long-term efficacy of this approach in managing DRA.

DOI： 10.1159/000546771

PubMed

researchmap

Genetic and protein structure prediction analyses identify a rare pathogenic PKD1 variant causing autosomal dominant polycystic kidney disease.

Takamitsu Shiiya, Hirofumi Watanabe, Ryo Aida, Tadashi Otsuka, Ryohei Kaseda, Suguru Yamamoto, Yoshikatsu Kaneko, Shin Goto, Ichiei Narita

CEN case reports 14 ( 4 ) 612 - 617 2025年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenic kidney disorders. The diagnosis of ADPKD requires imaging findings showing multiple kidney cysts or genetic testing, in cases where a family history is unknown. We report a patient diagnosed with ADPKD based on the identification of a rare PKD1 variant. The patient was a 41-year-old female in whom cysts and calcification in the kidneys were incidentally detected. Whole-exome sequencing identified a rare PKD1 variant (NM_001009944.3: c.11557G > A/p.E3853K). Protein structure prediction of the PKD1-PKD2 complex showed that the variant may be pathogenic, leading to the diagnosis of autosomal dominant polycystic kidney disease. A detailed family history revealed that her relatives also had ADPKD, further supporting the diagnosis of ADPKD. Comprehensive genetic analysis and protein structure prediction led to the diagnosis of ADPKD and the identification of rare causative genes. These methods are useful for diagnosing hereditary kidney diseases of unknown etiologies.

DOI： 10.1007/s13730-025-00985-4

PubMed

researchmap

Tsukamurella conjunctivitidis peritonitis diagnosed by 16S rRNA gene sequencing in a patient undergoing peritoneal dialysis. 査読

Masato Habuka, Kosuke Matsunaga, Asa Ogawa, Takashi Yaguchi, Suguru Yamamoto, Yoshinari Tanabe

CEN case reports 14 ( 4 ) 553 - 557 2025年8月

An end-stage kidney disease patient undergoing dialysis treatment for 50 years with dialysis-related amyloidosis in multiple organs. 査読

Toru Ito, Takashi Kato, Suguru Yamamoto, Hisaki Shimada, Hideyuki Kabasawa, Shin Goto, Riuko Ohashi, Ichiei Narita

CEN case reports 14 ( 4 ) 665 - 673 2025年8月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Advancements in dialysis treatment have led to an increase in the number of patients undergoing long-term dialysis. These patients often experience a decline in activities of daily living (ADL) owing to various chronic kidney disease-related conditions such as mineral and bone disorders, dialysis-related amyloidosis (DRA), and cardiovascular diseases. A male patient began hemodialysis at the age of 22 years because of end-stage kidney disease caused by chronic glomerulonephritis and continued dialysis treatment for 50 years. The patient died at 72 years of age from sepsis, ischemic colitis, and pneumonia. During the course of treatment, the patient frequently underwent surgeries for carpal tunnel syndrome and destructive spondyloarthropathy, which led to a decline in ADL. An autopsy revealed β2-microglobulin amyloid deposits in multiple organs, including the heart, lungs, and intestines. Long-term dialysis treatment results in ADL impairment owing to osteoarticular disorders caused by DRA, and systemic organ deposits are potentially related to organ failures such as ischemic colitis and pneumonia. Elucidating the pathophysiology of DRA and developing more effective treatments may improve ADL and prognosis in patients undergoing long-term dialysis.

DOI： 10.1007/s13730-025-01003-3

PubMed

researchmap

長期に治療を受けているSLE患者の脆弱性骨折は骨密度よりSLE疾患活動性や感染症入院が関連する

佐藤弘恵, 近藤直樹, 渡井友也, 坂井俊介, 長谷川絵理子, 若松彩子, 野澤由貴子, 小林大介, 黒田毅, 山本卓

日本骨粗鬆症学会雑誌 11 ( Suppl.1 ) 357 - 357 2025年8月

Diospyrobezoar (Persimmon Bezoar)-Induced Intestinal Obstruction in an Older Patient: A Case Report. 査読国際誌

Masato Habuka, Moeri Yamagiwa, Masataka Yonezawa, Asa Ogawa, Suguru Yamamoto

Cureus 17 ( 7 ) e87850 2025年7月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

Diospyrobezoar is a bezoar caused by excessive persimmon (Diospyros kaki) consumption, typically occurring in individuals with risk factors such as a history of gastric surgery, diabetes, or advanced age. We report the case of a 93-year-old man who presented with anorexia, nausea, and vomiting. Computed tomography revealed a bezoar-induced obstruction in the proximal jejunum. Despite initial management with Coca-Cola (The Coca-Cola Company, Atlanta, Georgia, United States) lavage and endoscopic fragmentation, surgical intervention was required because of persistent symptoms and intestinal ulceration. A 5 × 5-cm mass composed of >98% tannin was removed, confirming the presence of a diospyrobezoar. Further history assessment revealed that the patient consumed two persimmons daily. The patient recovered uneventfully after surgery and was discharged with dietary guidance. The present case highlights the importance of identifying diospyrobezoar-induced intestinal obstruction in older persimmon consumers, even in the absence of common risk factors, such as prior gastric surgery or diabetes. Early diagnosis based on imaging findings and dietary history, followed by timely surgical treatment, is essential to prevent the development of severe complications. Moreover, educating patients about the risks of excessive persimmon consumption is essential to prevent this condition.

DOI： 10.7759/cureus.87850

PubMed

researchmap

Impact of Dialysis Duration and Frailty on Frailty Progression: A Japanese Nationwide Cohort Study

Kakuya Niihata, Noriaki Kurita, Ryohei Inanaga, Tatsunori Toida, Masanori Abe, Takao Masaki, Suguru Yamamoto

2025年6月

常染色体顕性Alport症候群と遺伝性心筋緻密化障害の合併例の遺伝子解析による原因変異の同定

相田涼, 渡辺博文, 椎谷貴光, 大塚忠司, 忰田亮平, 金子佳賢, 後藤眞, 山本卓

日本腎臓学会誌 67 ( 4 ) 510 - 510 2025年6月

長期レニン-アンジオテンシン系阻害による腎輸入細動脈肥厚と腎障害に対するネプリライシン阻害の保護効果

椎谷貴光, 渡辺博文, 相田涼, 大塚忠司, 忰田亮平, 金子佳賢, 後藤眞, 山本卓

日本腎臓学会誌 67 ( 4 ) 489 - 489 2025年6月

近位尿細管特異的蛋白ACSM2の急性腎障害回復過程における機能

渡辺博文, 椎谷貴光, 相田涼, 大塚忠司, 忰田亮平, 金子佳賢, 後藤眞, 山本卓

日本腎臓学会誌 67 ( 4 ) 498 - 498 2025年6月

Polyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study). 査読国際誌

Ryohei Terashima, Mototsugu Tanaka, Atsushi Hashimoto, Daiki Omori, Takahiro Tanaka, Haruna Miyazawa, Masahiro Ishizawa, Yoshihiko Tomita, Tomoko Ito, Yoshiyuki Koyama, Kokichi Saito, Suguru Yamamoto, Shin Goto, Ichiei Narita

Trials 26 ( 1 ) 171 - 171 2025年5月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Achieving rapid and secure hemostasis of the vascular access point is important for patients undergoing maintenance hemodialysis (HD). We developed a polyacrylic acid-polyvinylpyrrolidone (PAA-PVP) complex that absorbs moisture such as blood or sterilizing solution, forms a hydrogel, and adheres to the body's surface, thereby exerting a powerful hemostatic effect. This study aims to compare the effect of PAA-PVP complex versus a conventional non-woven fabric pad on hemostasis at the needle puncture vascular access site in patients on HD. METHODS: This open-label crossover randomized controlled trial will include 50 participants who undergo thrice-weekly HD. Participants in whom hemostasis requires more than 10 min by compression using a conventional pad or who have a severe skin problem at the needle puncture vascular access site will be excluded from the study. Participants will be randomized in a 1:1 ratio to receive either the PAA-PVP complex or conventional pads. Three consecutive weekly hemostatic tests will be performed at 11, 9, 7, 5, 3, and 1 min. The study will employ an individual 3+3 design in which participants in whom hemostasis is achieved in all three sessions in a week will be challenged to a shorter time in the three sessions of the next week. Those in whom hemostasis is achieved in two of three sessions will be tested at the same time point in the three sessions of the next week. The study treatment will be terminated if hemostasis is achieved in only one or none of the sessions, and the minimum time with three consecutive successes will be recorded as the hemostasis time. The primary endpoint, the hemostasis time on the arterial side of the vascular access, will be analyzed using mixed-effect models for repeated measures and include the hemostatic technique and group, period, and individual effects as covariates. DISCUSSION: The study will provide evidence on whether the PAA-PVP complex reduces hemostasis time of the vascular access compared to conventional pad in patients on HD. TRIAL REGISTRATION: jRCTs032220597 (Japan Registry of Clinical Trials; registered on January 30, 2023, https://jrct.niph.go.jp/latest-detail/jRCTs032220597 ).

DOI： 10.1186/s13063-025-08877-9

PubMed

researchmap

Ectopic Production of Parathyroid Hormone and Production of Parathyroid Hormone-related Protein in Dedifferentiated Endometrial Carcinoma Induced Severe Hypercalcemia. 査読

Takeru Ogino, Hirofumi Watanabe, Shoko Yamazaki, Megumi Kurosawa, Akiko Kobayashi, Naofumi Imai, Takahiro Taguchi, Hajime Umezu, Ryo Aida, Kazuki Watanabe, Tadashi Otsuka, Hideyuki Kabasawa, Ryohei Kaseda, Suguru Yamamoto, Kosuke Yoshihara, Shin Goto, Ichiei Narita

Internal medicine (Tokyo, Japan) 64 ( 7 ) 1053 - 1059 2025年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Hypercalcemia is a significant complication in cancer patients, primarily caused by parathyroid hormone-related peptide (PTHrP) and, rarely, by parathyroid hormone (PTH) production from tumors. We report a case of severe hypercalcemia in a woman with uterine cancer who exhibited elevated PTH and PTHrP levels. Surgical intervention revealed dedifferentiated endometrial carcinoma. Postoperatively, PTH and PTHrP levels normalized but subsequently increased due to metastases. A molecular analysis confirmed the expression of the PTH gene and protein within the tumor, indicating ectopic PTH production. In diagnosing and treating cancers, it is necessary to consider not only PTHrP production but also ectopic PTH production.

DOI： 10.2169/internalmedicine.3899-24

PubMed

researchmap

Nephrotic syndrome induces the upregulation of cell proliferation-related genes in tubular cells in mice. 査読

Yuya Suzuki, Ryohei Kaseda, Yusuke Nakagawa, Hirofumi Watanabe, Tadashi Otsuka, Suguru Yamamoto, Yoshikatsu Kaneko, Shin Goto, Taiji Matsusaka, Ichiei Narita

Clinical and experimental nephrology 29 ( 4 ) 393 - 404 2025年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Abstract

Background

Massive proteinuria, dyslipidemia, and hypoalbuminemia induced by nephrotic syndrome (NS) secondarily affect tubular cells. We conducted an RNA sequencing (RNA-seq) analysis using a mouse model of focal segmental glomerulosclerosis to clarify the impact of NS on tubular cells.

Methods

We used transgenic mice expressing hCD25 in podocytes (Nep25) to induce NS by injecting human CD25-specific immunotoxin (LMB2) at a dose of 0.625 ng/g body weight. Seven days after LMB2 injection, we extracted RNA from the whole kidney and conducted an RNA-seq analysis. Subsequently, we conducted multiple immunostaining and in situ hybridization (ISH) of differentially expressed genes (DEGs) to identify their locations and associated cell types. We also investigated the expression levels of DEGs in an additional mouse model of NS induced by adriamycin.

Results

After NS induction, 562 upregulated and 430 downregulated DEGs were identified using RNA-seq. An enrichment analysis revealed the upregulation of cell proliferation-related genes. We observed significant upregulation of Foxm1, a transcription factor linked to cell proliferation. Immunostaining and ISH showed that various tubular cells expressed Mki67 and Foxm1 during NS development. The adriamycin-induced NS model also demonstrated the upregulation of Mki67 and Foxm1 in tubular cells.

Conclusions

NS induced the upregulation of cell proliferation-related genes in tubular cells without detectable renal dysfunction. Our findings may contribute to understanding the pathological effects of nephrotic syndrome on tubular cells.

DOI： 10.1007/s10157-024-02608-1

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1007/s10157-024-02608-1/fulltext.html

Author's Reply to the Letter to the Editor: Is the "Nutritional Risk Index for Japanese Hemodialysis" Validated as a Nutritional and Prognostic Indicator? 国際誌

Katsuhito Mori, Yosuke Yamamoto, Norio Hanafusa, Suguru Yamamoto, Shingo Fukuma, Yoshihiro Onishi, Masanori Emoto, Masaaki Inaba

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 35 ( 2 ) 370 - 372 2025年3月

A case of multiorgan failure due to carbamazepine intoxication successfully treated with multimodal blood purification therapy. 査読

Chihiro Sakurazawa, Masato Habuka, Yoshifumi Hoshino, Yuichi Sakamaki, Asa Ogawa, Suguru Yamamoto, Hidenori Kinoshita, Ichiei Narita

CEN case reports 14 ( 1 ) 29 - 33 2025年2月

A case of a cerebellar form of progressive multifocal leukoencephalopathy in a patient undergoing peritoneal dialysis. 査読

Yu Waraya, Masato Habuka, Chihiro Sakurazawa, Yuichi Sakamaki, Asa Ogawa, Junsuke Shimbo, Kazuo Nakamichi, Suguru Yamamoto, Ichiei Narita

CEN case reports 14 ( 1 ) 6 - 10 2025年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease of the central nervous system, is caused by the reactivation of the polyomavirus JC virus (JCV). It favors the cerebrum and typically occurs in patients with immunodeficiencies, with a progressive course and fatal outcome in the majority of cases. However, the cerebellar form of PML, characterized by isolated posterior fossa lesions, such as those in the cerebellum or brainstem at disease onset, is rare, and reports of its occurrence in peritoneal dialysis (PD) patients are lacking. In this paper, we describe a rare case of a cerebellar form of PML in a PD patient. A 64-year-old man undergoing PD was referred to our hospital for anorexia, nausea, and vomiting in the past month. He had finger-to-nose test abnormalities, gaze-directed nystagmus, and scanning speech. He was diagnosed with the cerebellar form of PML based on his progressive cerebellar symptoms, the typical magnetic resonance imaging findings, and the presence of JCV-DNA in the cerebrospinal fluid polymerase chain reaction test. He developed nocturnal delirium, aggravated disquiet, and died of pneumonia on the 69th day. Clinicians should consider the cerebellar form of PML as a differential diagnosis if PD patients develop progressive cerebellar symptoms.

DOI： 10.1007/s13730-024-00896-w

PubMed

researchmap

Peristaltic pump-triggered amyloid formation suggests shear stresses are in vivo risks for amyloid nucleation 査読

Yuji Goto, Tomoki Ota, Wenlou Yuan, Ikuko Yumen, Keiichi Yamaguchi, Hirokazu Matsuda, Suguru Yamamoto, Hirotsugu Ogi

npj Biosensing 2 ( 1 ) 2025年1月

Effect of increased fear of falling on falls in patients undergoing HD: A narrative review. 査読

Nobuyuki Shirai, Shinichiro Morishita, Yutaka Osawa, Suguru Yamamoto

Fukushima journal of medical science 71 ( 1 ) 13 - 24 2025年1月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

Increased fear of falling (FOF) increases the risk of falling and is an important issue for living an independent life. Patients undergoing hemodialysis (HD) frequently fall, and this may be attributed to increased FOF due to common fall risk factors as well as severe chronic kidney disease and HD-related factors. The purpose of this narrative review was to summarize the current knowledge on the mechanisms of increased FOF leading to falls in patients undergoing HD. Patients undergoing HD have enhanced FOF compared to community elderly people. Furthermore, an increase in FOF is correlated with a decrease in physical activity and physical function. It has been reported that FOF in patients undergoing HD may be associated with past and future falls, and the risk of falling increases sharply when FOF exceeds a certain threshold. Increased FOF may serve as a fundamental mechanism leading to increased fall risk by interacting with physical inactivity and physical frailty, affecting lower limb muscle activity during walking. Further research is needed to clarify the relationship between increased FOF and falls in patients undergoing HD. Regular clinical assessment of FOF is critical for identifying fall risk in patients undergoing HD.

DOI： 10.5387/fms.24-00014

PubMed

researchmap

Nutritional changes in patients undergoing hemodialysis who develop COVID-19 査読

Kou Kitabayashi, Suguru Yamamoto, Shin Goto

Renal Replacement Therapy 2025年1月

Association of Nutritional Risk Index With Infection-Related Hospitalization and Death After Hospitalization in Patients Undergoing Maintenance Hemodialysis. 国際誌

Katsuhito Mori, Yosuke Yamamoto, Norio Hanafusa, Suguru Yamamoto, Shingo Fukuma, Yoshihiro Onishi, Masanori Emoto, Masaaki Inaba

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 35 ( 1 ) 187 - 195 2025年1月

Systemic AA amyloidosis with amyloid deposition in the peritoneum at the time of initiating peritoneal dialysis 査読

Masato Habuka, Chihiro Sakurazawa, Yuichi Sakamaki, Asa Ogawa, Suguru Yamamoto, Ichiei Narita

CEN Case Reports 14 ( 3 ) 408 - 412 2025年

Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label, randomized controlled trial (the jDAPA-PD study) 査読

Suguru Yamamoto

Renal Replacement Therapy 11 2025年

Fanconi syndrome with acute proximal tubular injury induced by a dietary supplement containing beni-koji: a case series report. 査読国際誌

Masato Habuka, Michihiro Hosojima, Yusuke Yata, Kenshiro Kurumada, Moeri Yamagiwa, Masataka Yonezawa, Masanori Sudo, Hideyuki Kabasawa, Asa Ogawa, Hitomi Hama, Yumi Ito, Naofumi Imai, Suguru Yamamoto, Akihiko Saito, Shin Goto

BMC nephrology 25 ( 1 ) 446 - 446 2024年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Fanconi syndrome is a disorder of the proximal tubule that leads to malabsorption of various electrolytes and substances and is a common consequence of drug-induced nephrotoxicity. However, cases of dietary supplement-induced Fanconi syndrome are rare, and detailed reports on the evaluation of renal histology in patients with this syndrome are lacking. CASE PRESENTATION: We present two cases of dietary supplement-induced Fanconi syndrome that was confirmed by kidney biopsy. Based on their medical history and laboratory and histological findings, both cases were diagnosed as acute proximal tubular injury caused by ingestion of a lipid-lowering dietary supplement containing beni-koji leading to Fanconi syndrome. After discontinuation of the dietary supplement and correction of dehydration and electrolyte imbalance, renal function completely recovered in one case but progressed to chronic kidney disease in the other. CONCLUSIONS: Clinicians should consider dietary supplement-induced Fanconi syndrome as a differential diagnosis in patients who become ill while taking a dietary supplement. Kidney biopsy is useful for diagnosing acute tubular injury with Fanconi syndrome and investigating its pathogenesis. Patients who have developed dietary supplement-induced Fanconi syndrome require long-term monitoring to detect and prevent progression to chronic kidney disease.

DOI： 10.1186/s12882-024-03903-5

PubMed

researchmap

わが国の慢性透析療法の現況(2023年12月31日現在)

正木崇生, 花房規男, 阿部雅紀, 常喜信彦, 星野純一, 谷口正智, 菊地勘, 長谷川毅, 後藤俊介, 駒場大峰, 中井滋, 長沼俊秀, 福間真悟, 三浦健一郎, 山本卓, 和田篤志, 友雅司, 日本透析医学会統計調査委員会

日本透析医学会雑誌 57 ( 12 ) 543 - 620 2024年12月

Frailty and Duration of Maintenance Dialysis: A Japanese Nationwide Cross-Sectional Study. 査読国際誌

Suguru Yamamoto, Kakuya Niihata, Tatsunori Toida, Masanori Abe, Norio Hanafusa, Noriaki Kurita

American journal of kidney diseases : the official journal of the National Kidney Foundation 84 ( 5 ) 601 - 612 2024年11月

網羅的遺伝子解析と蛋白構造予測で病原PKD1バリアントを同定し常染色体顕性(優性)多発性嚢胞腎と診断した一例

椎谷貴光, 渡辺博文, 相田涼, 大塚忠司, 忰田亮平, 山本卓, 金子佳賢, 後藤眞

日本腎臓学会誌 66 ( 6-E ) 899 - 899 2024年9月

近位尿細管に限局した上皮細胞障害を呈したサプリメントによるファンコニー症候群の1例

羽深将人, 蒲澤秀門, 細島康宏, 小川麻, 山本卓, 伊藤由美, 今井直史, 後藤眞

日本腎臓学会誌 66 ( 6-E ) 892 - 892 2024年9月

マルチビタミンの長期過剰摂取による高Ca血症の遷延と二次性シュウ酸腎症を認めた一例

入沢大喜, 逸見太郎, 後藤佐和子, 蒲澤秀門, 細島康宏, 伊藤由美, 今井直史, 山本卓, 後藤眞, 成田一衛

日本腎臓学会誌 66 ( 6-E ) 889 - 889 2024年9月

網羅的遺伝子解析と蛋白構造予測で病原PKD1バリアントを同定し常染色体顕性(優性)多発性嚢胞腎と診断した一例

椎谷貴光, 渡辺博文, 相田涼, 大塚忠司, 忰田亮平, 山本卓, 金子佳賢, 後藤眞

日本腎臓学会誌 66 ( 6-E ) 899 - 899 2024年9月

Supersaturation, a Critical Factor Underlying Proteostasis of Amyloid Fibril Formation. 国際誌

Yuji Goto, Kichitaro Nakajima, Suguru Yamamoto, Keiichi Yamaguchi

Journal of molecular biology 436 ( 14 ) 168475 - 168475 2024年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

From a physicochemical viewpoint, amyloid fibril formation is a phase transition from soluble to crystal-like sates limited by supersaturation. It occurs only above solubility (i.e., the solubility limit) coupled with a breakdown of supersaturation. Although many studies have examined the role of molecular chaperones in the context of proteostasis, the role of supersaturation has not been addressed. Moreover, although molecular chaperone-dependent disaggregations have been reported for preformed amyloid fibrils, amyloid fibrils will not dissolve above the solubility of monomers, even if agitations fragment long fibrils to shorter amyloid particles. On the other hand, on considering a reversible and coupled equilibrium of interactions, folding/unfolding and amyloid formation/disaggregation, molecules stabilizing native states can work as a disaggregase reversing the amyloid fibrils to monomers. It is likely that the proteostasis network has various intra- and extracellular components which disaggregate preformed amyloid fibrils as well as prevent amyloid formation. Further studies with a view of solubility and supersaturation will be essential for comprehensive understanding of proteostasis.

DOI： 10.1016/j.jmb.2024.168475

PubMed

researchmap

The combined effect of leucine-enriched essential amino acid supplements and locomotion training on physical functions and quality of life in hemodialysis patients 査読

Kou Kitabayashi, Suguru Yamamoto, Yumi Katano, Ichiei Narita

Renal Replacement Therapy 2024年6月

Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis. 査読国際誌

Suguru Yamamoto, Keiko Yamamoto, Yoshitoshi Hirao, Keiichi Yamaguchi, Kichitaro Nakajima, Mami Sato, Miho Kawachi, Mio Domon, Kei Goto, Kentaro Omori, Noriaki Iino, Hisaki Shimada, Ryuzi Aoyagi, Isei Ei, Shin Goto, Yuji Goto, Fumitake Gejyo, Tadashi Yamamoto, Ichiei Narita

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 31 ( 2 ) 105 - 115 2024年6月

Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis. 査読国際誌

Takuya Wakamatsu, Suguru Yamamoto, Shiori Yoshida, Ichiei Narita

Toxins 16 ( 6 ) 254 2024年5月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Cardiovascular disease (CVD) frequently occurs in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The mechanisms behind this may be related to traditional risk factors and CKD-specific factors that accelerate atherosclerosis and vascular calcification in CKD patients. The accumulation of uremic toxins is a significant factor in CKD-related systemic disorders. Basic research suggests that indoxyl sulfate (IS), a small protein-bound uremic toxin, is associated with macrophage dysfunctions, including increased oxidative stress, exacerbation of chronic inflammation, and abnormalities in lipid metabolism. Strategies to mitigate the toxicity of IS include optimizing gut microbiota, intervening against the abnormality of intracellular signal transduction, and using blood purification therapy with higher efficiency. Further research is needed to examine whether lowering protein-bound uremic toxins through intervention leads to a reduction in CVD in patients with CKD.

DOI： 10.3390/toxins16060254

PubMed

researchmap

Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials 査読

Takuya Wakamatsu, Suguru Yamamoto, Koji Matsuo, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa, Junichiro James Kazama

Journal of Bone and Mineral Metabolism 42 ( 3 ) 316 - 325 2024年5月

Protein intake and its relationship with frailty in chronic kidney disease. 査読

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Toshiko Murayama, Ichiei Narita

Clinical and experimental nephrology 28 ( 5 ) 447 - 453 2024年5月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Patients with chronic kidney disease (CKD) are susceptible to frailty because of a range of nutrition-related factors. While protein restriction is commonly advised to preserve kidney function in patients with CKD, insufficient protein intake could potentially exacerbate frailty risk. This study aimed to elucidate the relationship between frailty and protein intake in patients with CKD. METHODS: This cross-sectional study enrolled patients with CKD stage 3-5. Frailty and prefrailty were assessed using the Japanese version of the Cardiovascular Health Study (J-CHS) criteria. To estimate dietary protein intake, Maroni's formula based on 24-h urine collection was used. The potential association between frailty/pre-frailty and protein intake was investigated using a logistic regression analysis. RESULTS: Ninety-seven individuals with CKD were included in the study, with a median age of 73.0 years (interquartile range: 67.0, 82.0). Among them, 34 were women (35.1%), and the estimated glomerular filtration rate (eGFR) was 36.3 mL/min/1.73 m2 (interquartile range: 26.9, 44.1). Frailty and pre-frailty were identified in 13.4% and 55.7% of participants, respectively. Comparing the groups, protein intake in the frailty/pre-frailty group (0.83 g/kgBW/day [0.72, 0.93]) was lower than that in the robust group (0.89 g/kgBW/day [0.84, 1.19], p = 0.002). Upon logistic regression analysis, protein intake exhibited an independent association with frailty/pre-frailty (odds ratio: 0.72, 95% confidence interval: 0.59-0.89, p = 0.003). CONCLUSION: Reduced protein intake in patients with CKD is associated with frailty and pre-frailty. It is advisable to ensure that patients with CKD who are at risk of frailty consume an adequate amount of protein.

DOI： 10.1007/s10157-023-02452-9

PubMed

researchmap

シングルルーメンカテーテル有用性の検討

吉澤優太, 大塚忠司, 山本卓, 永野敦嗣, 甲田亮, 飯野則昭, 宮崎慧, 若松拓也, 飯田倫理, 青柳竜治, 伊藤徹, 亀田茂美

日本透析医学会雑誌 57 ( Suppl.1 ) 619 - 619 2024年5月

慢性腎臓病患者の腰椎海綿骨スコアと骨塩量横断研究

齋藤耕吉, 山本卓, 若松拓也, 風間順一郎

日本骨形態計測学会雑誌 34 ( 1 ) 152 - 152 2024年5月

Correction to: Protein intake and its relationship with frailty in chronic kidney disease.

Nobuyuki Shirai, Suguru Yamamoto, Yutaka Osawa, Atsuhiro Tsubaki, Shinichiro Morishita, Toshiko Murayama, Ichiei Narita

Clinical and experimental nephrology 28 ( 5 ) 454 - 456 2024年5月

慢性腎臓病における感染症の重症化に関連する因子の検討

若松拓也, 山本卓, 成田一衛

新潟県医師会報 ( 888 ) 8 - 9 2024年3月

Systemic Amyloid A Amyloidosis Secondary to Xanthogranulomatous Pyelonephritis. 査読

Masato Habuka, Mizusa Nishikiori, Chihiro Oikawa, Megumi Takahashi, Yuichi Sakamaki, Asa Ogawa, Norio Miyajima, Yasuhiko Tanabe, Keiichi Honma, Kunihiko Wakaki, Suguru Yamamoto, Ichiei Narita

Internal medicine (Tokyo, Japan) 63 ( 4 ) 593 - 599 2024年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

The combination of systemic amyloid A (AA) amyloidosis and xanthogranulomatous pyelonephritis (XGP) resulting from a chronic urinary tract infection is extremely rare. We herein report a case of systemic AA amyloidosis secondary to XGP for which clinical remission developed after nephrectomy. To our knowledge, this is the first case report describing the clinical improvement of systemic AA amyloidosis secondary XGP after nephrectomy in Japan. Clinicians should be aware of this uncommon combination and search for amyloid depositions in cases of XGP.

DOI： 10.2169/internalmedicine.1806-23

PubMed

researchmap

シングルルーメンカテーテルの有用性について

吉澤優太, 大塚忠司, 山本卓, 永野敦嗣, 甲田亮, 飯野則昭, 宮崎慧, 若松拓也, 飯田倫理, 青柳竜治, 伊藤徹, 亀田茂美, 成田一衛

Niigata Blood Purification Conferenceプログラム・一般演題抄録 2023 10 - 10 2023年12月

Hemolysis Precedes Urine Color Change in Patients Undergoing Open-Heart Surgery on Cardiopulmonary Bypass. 国際誌

Kenta Takeishi, Suguru Yamamoto, Yasuto Sato, Osamu Takahashi, Nobuko Fujita, Kohei Abe, Yoko Fukui, Megumi Kameda, Tokujiro Uchida, Yasuko Nagasaka

Cureus 15 ( 12 ) e49971 2023年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

PURPOSE: Red-colored urine often occurs in patients in the perioperative period who undergo cardiac surgery using cardiopulmonary bypass (CPB). This urine color change has been utilized for approximating hemolysis during CPB without a proven relationship for ongoing hemolysis. This case series study aimed to examine the relationship between plasma free hemoglobin (Hb) levels and quantified measures of urine color. METHODS: Ten patients were enrolled in this study. Blood and urine were collected for analyses for the following time points: before surgery, two hours after the initiation of CPB, every 30 min during CPB thereafter, and 0, 2, 4, 12, and 24 hours after the completion of CPB. We measured free Hb in plasma and urine using the azide-methemoglobin method. Photographs of urine were obtained, and the luminance of the three basic colors (red/green/blue) was analyzed by quantitative luminance contrast analysis to find a correlation for hemolysis. RESULTS: Median levels of plasma free Hb were 0.015 (0.010-0.080, n = 10) g/dL at baseline. During the CPB, increases in plasma free Hb levels were measured: median plasma free Hb levels were increased to 0.100 g/dL (0.020-0.240, p = 0.039, vs. baseline, n = 9) at two hours into CPB, median and range, respectively. In contrast, increases in urinary free Hb levels and/or urine color changes were measured only after cessation of CPB in nine patients. CONCLUSION: Urine color change or elevation of urinary free Hb levels followed the elevation of plasma free Hb levels with considerable delay.

DOI： 10.7759/cureus.49971

PubMed

researchmap

Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS. 査読国際誌

Hirotaka Komaba, Junhui Zhao, Angelo Karaboyas, Suguru Yamamoto, Indranil Dasgupta, Mohamed Hassan, Li Zuo, Anders Christensson, Christian Combe, Bruce M Robinson, Masafumi Fukagawa

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 38 ( 11 ) 1577 - 1585 2023年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Active vitamin D is commonly used to control secondary hyperparathyroidism in dialysis patients, but it is unknown whether active vitamin D directly improves bone strength, independent of its effect to suppress parathyroid hormone (PTH). We analyzed the association between prescription of active vitamin D and incidence of any fracture and hip fracture in 41,677 in-center hemodialysis patients from 21 countries in phases 3-6 (2005-2018) of the Dialysis Outcomes and Practice Patterns Study (DOPPS). We used Cox regression, adjusted for PTH and other potential confounders, and used a per-protocol approach to censor patients at treatment switch during follow-up. We also used a facility preference approach to minimize confounding by indication. Overall, 55% of patients were prescribed active vitamin D at study enrollment. Event rates (per patient-year) were 0.024 for any fracture and 0.010 for hip fracture. The adjusted hazard ratio (95% confidence interval) comparing patients prescribed vs. not prescribed active vitamin D was 1.02 (0.90-1.17) for any fracture and 1.00 (0.81-1.23) for hip fracture. In the facility preference approach, there was no difference in fracture rate between facilities with higher vs. lower active vitamin D prescriptions. Thus, our results do not suggest a PTH-independent benefit of active vitamin D in fracture prevention and support the current KDIGO guideline suggesting the use of active vitamin D only in subjects with elevated or rising PTH. Further research is needed to determine the role of active vitamin D beyond PTH control. This article is protected by copyright. All rights reserved.

DOI： 10.1002/jbmr.4913

PubMed

researchmap

Frailty in Patients on Dialysis Surviving for More than 40 Years is Common and Severe: A Nationwide Cross-Sectional Study

Yamamoto Suguru, Niihata Kakuya, Toida Tatsunori, Abe Masanori, Hanafusa Norio, Kurita Noriaki

SSRN (プレプリント) 2023年10月

Assessing fluid volume and determining outcomes of acute heart failure using plasma human atrial natriuretic peptide. 査読

Yuya Suzuki, Tadashi Otsuka, Yuki Yoshioka, Tomomichi Iida, Shingo Maruyama, Hirofumi Watanabe, Ryohei Kaseda, Suguru Yamamoto, Yoshikatsu Kaneko, Shin Goto, Ryuji Aoyagi, Ichiei Narita

Clinical and experimental nephrology 27 ( 6 ) 565 - 573 2023年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The post-dialysis plasma level of human atrial natriuretic peptide (hANP) reflects the fluid volume in patients on hemodialysis. The threshold hANP level is reportedly 100 pg/mL; however, the clinical usefulness of the threshold hANP level for volume control has not been sufficiently studied. METHODS: We conducted a single-center, retrospective, observational study that included 156 hemodialysis patients without atrial fibrillation. First, we examined the usefulness of the threshold hANP level (100 pg/mL) for predicting hypoxemia due to congestion in a short-term observational study from December 30, 2015 to January 5, 2016. Subsequently, we conducted a 5-year follow-up study wherein the outcomes were hospitalization due to acute heart failure (AHF), development of cardiovascular diseases (CVD), and all-cause death. Finally, we collected echocardiography data to investigate the relationship between cardiac function and hANP. RESULTS: Our short-term observational study showed that patients with an hANP level ≥ 100 pg/mL developed hypoxemia due to congestion (odds ratio, 3.52; 95% confidence interval, 1.06-11.71; P = 0.040). At the 5-year follow-up, patients with an hANP level ≥ 100 pg/mL had significantly higher rates of hospitalization due to AHF, CVD, and all-cause death based on the log-rank test (P = 0.003, P = 0.019, P < 0.001, respectively). Cardiac disfunctions were significantly associated with the high hANP level. CONCLUSIONS: The hANP level is indicative of both fluid volume and cardiac dysfunction. A threshold hANP level of 100 pg/mL can serve as a predictive marker for AHF and a practical indicator for volume control.

DOI： 10.1007/s10157-023-02333-1

PubMed

researchmap

Sodium Magnetic Resonance Imaging Shows Impairment of the Counter-current Multiplication System in Diabetic Mice Kidney. 査読国際誌

Yusuke Nakagawa, Ryohei Kaseda, Yuya Suzuki, Hirofumi Watanabe, Tadashi Otsuka, Suguru Yamamoto, Yoshikatsu Kaneko, Shin Goto, Yasuhiko Terada, Tomoyuki Haishi, Susumu Sasaki, Ichiei Narita

Kidney360 4 ( 5 ) 582 - 590 2023年5月

記述言語：英語掲載種別：研究論文（学術雑誌）

Sodium magnetic resonance imaging can non-invasively assess sodium distribution, specifically sodium concentration in the countercurrent multiplication system in the kidney, which forms a sodium concentration gradient from the cortex to the medulla, enabling efficient water reabsorption. This study aimed to investigate whether sodium magnetic resonance imaging can detect changes in sodium concentrations under normal conditions in mice and in disease models such as a mouse model with diabetes mellitus. Methods: We performed sodium and proton nuclear magnetic resonance imaging using a 9.4-T vertical standard-bore super-conducting magnet. Results: A condition of deep anesthesia, with widened breath intervals, or furosemide administration in 6-week-old C57BL/6JJcl mice showed a decrease in both tissue sodium concentrations in the medulla and sodium concentration gradients from the cortex to the medulla. Further, sodium magnetic resonance imaging revealed reductions in the sodium concentration of the medulla and in the gradient from the cortex to the medulla in BKS.Cg-Leprdb+/+ Leprdb/Jcl mice at very early type-2 diabetes mellitus stages compared to corresponding control BKS.Cg-m+/m+/Jcl mice. Conclusions: The kidneys of BKS.Cg-Leprdb+/+ Leprdb/Jcl mice aged 6 weeks showed impairments in the countercurrent multiplication system. We propose the utility of 23Na MRI for evaluating functional changes in diabetic kidney disease, not as markers that reflect structural damage. Thus, 23Na MRI may be a potential very early marker for structures beyond the glomerulus; this may prompt intervention with novel efficacious tubule-targeting therapies.

DOI： 10.34067/KID.0000000000000072

PubMed

researchmap

THE EVALUATION OF FLUID VOLUME AND PROGNOSIS IN HEMODIALYSIS PATIENTS UTILIZING PLASMA HUMAN ATRIAL NATRIURETIC PEPTIDE

Suguru Yamamoto

Nephrology Dialysis Transplantation 2023年

Bilateral refractory pneumothorax treated by pleurodesis and bronchial occlusion in a COVID-19 patient. 国際誌

Satoshi Tanaka, Yoshihiro Takayama, Riiko Kitou, Ryo Asakawa, Satoshi Tobita, Akihiro Ike, Masahiro Kawada, Suguru Yamamoto, Kiyonobu Ueno

Clinical case reports 10 ( 12 ) e6754 2022年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

Coronavirus disease 2019 (COVID-19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID-19 is relatively uncommon. We herein report a 60-year-old man with bilateral refractory pneumothorax with severe COVID-19. In patients with poor general health and who are difficult to undergo surgery for pneumothorax post-COVID-19, internal treatments such as chest drainage, bronchial occlusion, and pleurodesis are essential to relieving refractory pneumothorax. It also indicates that autologous blood patch pleurodesis is a useful method in terms of efficacy and side effects.

DOI： 10.1002/ccr3.6754

PubMed

researchmap

Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. 査読国際誌

Hirotaka Komaba, Junhui Zhao, Suguru Yamamoto, Takanobu Nomura, Douglas S Fuller, Keith P McCullough, Pieter Evenepoel, Anders Christensson, Xinju Zhao, Mona Alrukhaimi, Fadwa Al-Ali, Eric W Young, Bruce M Robinson, Masafumi Fukagawa

Journal of cachexia, sarcopenia and muscle 12 ( 4 ) 855 - 865 2021年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

BACKGROUND: Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, weight loss, and risk of mortality in dialysis patients. METHODS: We included 42,319 chronic in-centre haemodialysis patients from the Dialysis Outcomes and Practice Patterns Study phases 2-6 (2002-2018). Linear mixed models were used to estimate the association between baseline PTH and percent weight change over 12 months, adjusting for country, demographics, comorbidities, and labs. Accelerated failure time models were used to assess 12 month weight loss as a mediator between baseline high PTH and mortality after 12 months. RESULTS: Baseline PTH was inversely associated with 12 month weight change: 12 month weight loss >5% was observed in 21%, 18%, 18%, 17%, 15%, and 14% of patients for PTH ≥600 pg/mL, 450-600, 300-450, 150-300, 50-150, and <50 pg/mL, respectively. In adjusted analyses, 12 month weight change compared with PTH 150-299 pg/mL was -0.60%, -0.12%, -0.10%, +0.15%, and +0.35% for PTH ≥600, 450-600, 300-450, 50-150, and <50 pg/mL, respectively. This relationship was robust regardless of recent hospitalization and was more pronounced in persons with preserved appetite. During follow-up after the 12 month weight measure [median, 1.0 (interquartile range, 0.6-1.7) years; 6125 deaths], patients with baseline PTH ≥600 pg/mL had 11% [95% confidence interval (CI), 9-13%] shorter lifespan, and 18% (95% CI, 14-23%) of this effect was mediated through weight loss ≥2.5%. CONCLUSIONS: Secondary hyperparathyroidism may be a novel mechanism of wasting, corroborating experimental data, and, among chronic dialysis patients, this pathway may be a mediator between elevated PTH levels and mortality. Future research should determine whether PTH-lowering therapy can limit weight loss and improve longer term dialysis outcomes.

DOI： 10.1002/jcsm.12722

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jcsm.12722

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. 国際誌

Toru Arai, Hiroto Matsuoka, Masaki Hirose, Hiroshi Kida, Suguru Yamamoto, Yoshitaka Ogata, Masahide Mori, Kazuyoshi Hatsuda, Chikatoshi Sugimoto, Kazunobu Tachibana, Masanori Akira, Yoshikazu Inoue

BMJ open respiratory research 8 ( 1 ) 2021年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Acute exacerbation (AE) has been reported to herald a poor prognosis in idiopathic pulmonary fibrosis and is now thought to do so in idiopathic interstitial pneumonias (IIPs). However, the pathophysiology of AE-IIPs is not sufficiently understood. In our previously reported SETUP trial, we found better survival in patients with AE-IIPs treated with corticosteroids and thrombomodulin than in those treated with corticosteroids alone. In that study, we collected serum samples to evaluate changes in cytokine levels and retrospectively examined the prognostic significance and pathophysiological role of serum cytokines in patients with AE-IIPs. METHODS: This study included 28 patients from the SETUP trial for whom serial serum samples had been prospectively obtained. AE-IIPs were diagnosed using the Japanese Respiratory Society criteria. All patients were treated with intravenous thrombomodulin and corticosteroids from 2014 to 2016. Serum levels of 27 cytokines were measured using Bio-Plex. The high-resolution CT pattern at the time of diagnosis of AE was classified as diffuse or non-diffuse. RESULTS: Univariate analysis revealed that higher serum levels of interleukin (IL)-2, IL-7, IL-9, IL-12, IL13, basic fibroblast growth factor, granulocyte-macrophage colony-stimulating factor, interferon-γ inducible protein-10, platelet-derived growth factor and regulated on activation, normal T cell expressed and secreted (RANTES) at AE were significant predictors of 90-day survival. The HRCT pattern was also a significant clinical predictor of 90-day survival. Multivariate analysis with stepwise selection identified a higher serum RANTES level at AE to be a significant predictor of 90-day survival, including after adjustment for HRCT pattern. Multivariate analysis with stepwise selection suggested that a marked increase in the serum IL-10 level on day 8 could predict 90-day mortality. CONCLUSIONS: A higher serum RANTES level at AE the time of diagnosis predicted a good survival outcome, and an elevated serum IL-10 level on day 8 predicted a poor survival outcome. TRIAL REGISTRATION NUMBER: UMIN000014969.

DOI： 10.1136/bmjresp-2021-000889

PubMed

researchmap

Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy 査読国際誌

Hiroki Yamaguchi, Shin Goto, Nao Takahashi, Masafumi Tsuchida, Hirofumi Watanabe, Suguru Yamamoto, Yoshikatsu Kaneko, Koichi Higashi, Hiroshi Mori, Yukio Nakamura, Arata Horii, Ken Kurokawa, Ichiei Narita

Nephrology Dialysis Transplantation 36 ( 1 ) 75 - 86 2021年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Background</title>
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by mesangial polymeric IgA1 deposition. IgAN is believed to develop owing to aberrant mucosal immunoreaction against commensals in the tonsils. However, the exact interrelation between pathogenic IgA and mucosal microbiota in IgAN patients is unclear.

</sec>
<sec>
<title>Methods</title>
Biopsy-proven IgAN or recurrent tonsillitis (RT) patients who had undergone tonsillectomy were enrolled. We used 16S ribosomal RNA gene amplicon sequencing with a flow cytometry-based bacterial cell sorting technique) and immunoglobulin repertoire sequencing of the IgA heavy chain to characterize IgA-coated bacteria of the tonsillar microbiota (IgA-SEQ) and their corresponding IgA repertoire. Furthermore, we fractionated patient serum using gel-filtration chromatography and performed flow cytometry-based analysis of IgA binding to bacteria cultured from incised tonsils.

</sec>
<sec>
<title>Results</title>
Tonsillar proliferation-inducing ligand and B-cell activating factor levels were significantly higher in IgAN than in RT patients. IgA-SEQ for tonsillar microbiota revealed the preferential binding ability of IgA to Bacteroidetes in IgAN tonsils compared with those from RT patients. Expression of immunoglobulin heavy (IGH) constant alpha 1 with IGH variable 3–30 was significantly higher in IgAN than that in RT, and positively correlated with the IgA-coated enrichment score of Bacteroidetes. Serum polymeric IgA, comprising high levels of GdIgA1, exhibited considerable binding to Bacteroidetes strains cultured from the tonsils of IgAN patients.

</sec>
<sec>
<title>Conclusions</title>
These findings provide evidence that aberrant mucosal immune responses to tonsillar anaerobic microbiota, primarily consisting of members of the phylum Bacteroidetes, are involved in IgAN pathophysiology.

</sec>

DOI： 10.1093/ndt/gfaa223

PubMed

researchmap

Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy. 国際誌

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 36 ( 1 ) 75 - 86 2021年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by mesangial polymeric IgA1 deposition. IgAN is believed to develop owing to aberrant mucosal immunoreaction against commensals in the tonsils. However, the exact interrelation between pathogenic IgA and mucosal microbiota in IgAN patients is unclear. METHODS: Biopsy-proven IgAN or recurrent tonsillitis (RT) patients who had undergone tonsillectomy were enrolled. We used 16S ribosomal RNA gene amplicon sequencing with a flow cytometry-based bacterial cell sorting technique) and immunoglobulin repertoire sequencing of the IgA heavy chain to characterize IgA-coated bacteria of the tonsillar microbiota (IgA-SEQ) and their corresponding IgA repertoire. Furthermore, we fractionated patient serum using gel-filtration chromatography and performed flow cytometry-based analysis of IgA binding to bacteria cultured from incised tonsils. RESULTS: Tonsillar proliferation-inducing ligand and B-cell activating factor levels were significantly higher in IgAN than in RT patients. IgA-SEQ for tonsillar microbiota revealed the preferential binding ability of IgA to Bacteroidetes in IgAN tonsils compared with those from RT patients. Expression of immunoglobulin heavy (IGH) constant alpha 1 with IGH variable 3-30 was significantly higher in IgAN than that in RT, and positively correlated with the IgA-coated enrichment score of Bacteroidetes. Serum polymeric IgA, comprising high levels of GdIgA1, exhibited considerable binding to Bacteroidetes strains cultured from the tonsils of IgAN patients. CONCLUSIONS: These findings provide evidence that aberrant mucosal immune responses to tonsillar anaerobic microbiota, primarily consisting of members of the phylum Bacteroidetes, are involved in IgAN pathophysiology.

DOI： 10.1093/ndt/gfaa223

PubMed

researchmap

Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties. 査読国際誌

Takuya Wakamatsu, Yoshiko Iwasaki, Suguru Yamamoto, Koji Matsuo, Shin Goto, Ichiei Narita, Junichiro J Kazama, Kennichi Tanaka, Akemi Ito, Ryosuke Ozasa, Takayoshi Nakano, Chisato Miyakoshi, Yoshihiro Onishi, Shingo Fukuma, Shunichi Fukuhara, Hideyuki Yamato, Masafumi Fukagawa, Tadao Akizawa

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 36 ( 1 ) 67 - 79 2021年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

Chronic kidney disease (CKD) is associated with a high incidence of fractures. However, the pathophysiology of this disease is not fully understood, and limited therapeutic interventions are available. This study aimed to determine the impact of type-1 angiotensin II receptor blockade (AT-1RB) on preventing CKD-related fragility fractures and elucidate its pharmacological mechanisms. AT-1RB use was associated with a lower risk of hospitalization due to fractures in 3276 patients undergoing maintenance hemodialysis. In nephrectomized rats, administration of olmesartan suppressed osteocyte apoptosis, skeletal pentosidine accumulation and apatite disorientation, and partially inhibited the progression of the bone elastic mechanical properties, while the bone mass unchanged. Olmesartan suppressed angiotensin II-dependent oxidation stress and apoptosis in primary cultured osteocytes in vitro. In conclusion, angiotensin II-dependent intraskeletal oxidation stress deteriorated the bone elastic mechanical properties by promoting osteocyte apoptosis and pentosidine accumulation. Thus, AT-1RB contributes to the underlying pathogenesis of abnormal bone quality in the setting of CKD, possibly by oxidative stress.

DOI： 10.1002/jbmr.4159

PubMed

researchmap

Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study. 査読国際誌

Hirotaka Komaba, Douglas S Fuller, Masatomo Taniguchi, Suguru Yamamoto, Takanobu Nomura, Junhui Zhao, Brian A Bieber, Bruce M Robinson, Ronald L Pisoni, Masafumi Fukagawa

Kidney international reports 5 ( 11 ) 1956 - 1964 2020年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier BV

INTRODUCTION: Elevated fibroblast growth factor 23 (FGF23) levels have been strongly associated with mortality in the predialysis and incident hemodialysis populations, but few studies have examined this relationship in a large cohort of prevalent hemodialysis patients and in particular among persons with high dialysis vintage. To address this, we analyzed data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS). METHODS: We included 1122 prevalent hemodialysis patients from the J-DOPPS phase 5 (2012-2015) who had FGF23 measurements. We evaluated the association of FGF23 levels with all-cause mortality and cardiovascular composite outcome using Cox regression adjusted for potential confounders. RESULTS: At study enrollment, median dialysis vintage was 5.8 years (interquartile range, 2.7-12.4 years) and median FGF23 level was 2113 pg/ml (interquartile range, 583-6880 pg/ml). During 3-year follow-up, 154 of the 1122 participants died. In adjusted analyses, higher FGF23 was associated with a greater hazard of death (hazard ratio per doubling of FGF23, 1.12; 95% confidence interval, 1.03-1.21); however, the association became weaker as the dialysis vintage increased and finally disappeared in the highest tertile (>9.4 years). Similar patterns of effect modification by dialysis vintage were observed for cardiovascular composite outcome and in time-dependent models. CONCLUSION: Elevated FGF23 was associated with mortality and cardiovascular events in prevalent hemodialysis patients, but the association was attenuated at longer dialysis vintages. This novel finding suggests that long-term hemodialysis patients may be less susceptible to the detrimental effects of FGF23 or correlated biological processes, and additional studies are needed to gain understanding of these possibilities.

DOI： 10.1016/j.ekir.2020.08.013

PubMed

researchmap

Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis. 査読

Akira Iguchi, Suguru Yamamoto, Akira Oda, Kenichi Tanaka, Junichiro James Kazama, Takako Saeki, Hajime Yamazaki, Ken Ishioka, Tatsuo Suzutani, Ichiei Narita

Clinical and experimental nephrology 24 ( 8 ) 725 - 733 2020年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: In patients with chronic kidney disease (CKD), dysbiosis in the gastrointestinal microbiome is thought to be associated with increased production of uremic toxins, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Sucroferric oxyhydroxide (SFO), an iron-based phosphate binder, may affect the gastrointestinal microbiome and the production of uremic toxins. We aimed to examine whether SFO administration affected distribution of gastrointestinal microbiome and serum uremic toxin levels in CKD patients undergoing hemodialysis. METHODS: In this single-center, open-label, interventional study, 18 maintenance hemodialysis patients with hyperphosphatemia were prescribed with SFO. We collected serum samples before and after 3 months of administration, and serum levels of IS and PCS were measured. A control group of 20 hemodialysis patients without SFO was evaluated. We evaluated gastrointestinal microbiome of patients pre- and post-SFO administration by 16S rDNA sequencing and bioinformatics analysis. RESULTS: Serum IS and PCS levels were significantly elevated after administration of SFO (IS before 2.52 ± 1.60 mg/dl vs. after 3.13 ± 1.51 mg/dl, P = 0.008; PCS before 2.32 ± 2.44 mg/dl vs. after 3.45 ± 2.11 mg/dl, P = 0.002), while serum IS and PCS levels did not change in the control group. Microbiome analysis in the SFO group showed no significant change in diversity and major components in phylum, class, order, family, gene, and species. CONCLUSION: Administration of SFO increased the serum levels of IS and PCS with no change of major components of gastrointestinal microbiome.

DOI： 10.1007/s10157-020-01892-x

PubMed

researchmap

SEVERITY OF PRURITUS IN HEMODIALYSIS PATIENTS: RELATIONSHIP TO UREMIC TOXINS AND DIALYSIS MODALITY

Suguru Yamamoto

Nephrology Dialysis Transplantation 2020年

PRIORITIZATION BY MEDICAL DIRECTORS OF NUTRITIONAL PROTEIN VERSUS DIETARY PHOSPHORUS CONTROL IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH MORTALITY IN THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)

Suguru Yamamoto

Nephrology Dialysis Transplantation 2020年

血液透析患者における透析実施時間帯の早朝空腹時呼吸商に及ぼす影響の検討

北林紘, 片野佑美, 山本卓, 石井雄士

日本栄養士会雑誌 62 ( 12 ) 641 - 647 2019年12月

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism. 査読

Sato T, Kikkawa Y, Yamamoto S, Tanaka Y, Kazama JJ, Tominaga Y, Ichimori T, Okada M, Hiramitsu T, Fukagawa M

Clinical kidney journal 12 ( 5 ) 686 - 692 2019年10月

Possible mechanisms of polyphosphate-induced amyloid fibril formation of β2-microglobulin. 査読

Zhang CM, Yamaguchi K, So M, Sasahara K, Ito T, Yamamoto S, Narita I, Kardos J, Naiki H, Goto Y

Proceedings of the National Academy of Sciences of the United States of America 116 ( 26 ) 12833 - 12838 2019年6月

The features of bone articular lesions in dialysis-related amyloidosis (DRA) and criteria for the clinical diagnosis of DRA 査読

Suguru Yamamoto

Renal Replacement Therapy 2019年5月

Cryofibrinogen-associated glomerulonephritis diagnosed by mass spectrometry and immunoelectron microscopy 査読

Masanori Sudo, Yuichi Sakamaki, Michihiro Hosojima, Suguru Yamamoto, Yumi Ito, Naofumi Imai, Yoshikatsu Kaneko, Shin Goto, Chih Ping Li, Akira Shimizu, Ichiei Narita

Human Pathology: Case Reports 15 83 - 87 2019年3月

Successful treatment of gamma 1 heavy chain deposition disease with bortezomib and dexamethasone

Suguru Yamamoto

Human Pathology: Case Reports 2019年

Attenuated Macrophage Infiltration in Glomeruli of Aged Mice Resulting in Ameliorated Kidney Injury in Nephrotoxic Serum Nephritis. 査読

Kaneko Y, Cho T, Sato Y, Goto K, Yamamoto S, Goto S, Madaio MP, Narita I

The journals of gerontology. Series A, Biological sciences and medical sciences 73 ( 9 ) 1178 - 1186 2018年8月

自己末梢血幹細胞移植後に血栓性微小血管症(TMA)による腎障害を合併した一例

白柏由佳, 後藤佐和子, 細島康宏, 保坂聖子, 山本卓, 今井直史, 伊藤由美, 後藤眞, 成田一衛

日本腎臓学会誌 60 ( 6 ) 876 - 876 2018年8月

Multicentre cross-sectional study for bone-articular lesions associated with dialysis related amyloidosis in Japan. 査読

Nishi S, Hoshino J, Yamamoto S, Goto S, Fujii H, Ubara Y, Motomiya Y, Morita H, Takaichi K, Yamagata K, Shigematsu T, Ueda M, Ando Y

Nephrology (Carlton, Vic.) 23 ( 7 ) 640 - 645 2018年7月

ABO血液型不適合生体腎移植前に行った二重膜濾過血漿交換施行中に全身膨隆疹を発症した一例

宮内大輔, 斎藤将名, 土田良樹, 谷江駿矢, 近藤友希, 長谷川進, 西塔毅, 田崎正行, 中川由紀, 齋藤和英, 蒲澤秀門, 山本卓, 成田一衛

日本臨床工学技士会会誌 ( 63 ) 194 - 194 2018年4月

Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis - Possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: A case report 査読

Masato Habuka, Yoko Wada, Yoichi Kurosawa, Suguru Yamamoto, Yusuke Tani, Riuko Ohashi, Yoichi Ajioka, Masaaki Nakano, Ichiei Narita

BMC Research Notes 11 ( 1 ) 165 2018年3月

Kidney morphological parameters measured using noncontrast-enhanced steady-state free precession MRI with spatially selective inversion recovery pulse correlate with eGFR in patients with advanced CKD 査読

Tadashi Otsuka, Yoshikatsu Kaneko, Yuya Sato, Ryohei Kaseda, Ryuji Aoyagi, Suguru Yamamoto, Shin Goto, Ichiei Narita

Clinical and Experimental Nephrology 22 ( 1 ) 45 - 54 2018年2月

INDOXYL SULFATE AND MORTALITY IN HAEMODIALYSIS PATIENTS: RESULTS FROM THE JAPAN DIALYSIS OUTCOMESAND PRACTICE PATTERNS STUDY (J-DOPPS)

Suguru Yamamoto

Nephrology Dialysis Transplantation 2018年

Suction towards a vessel wall by hemodialysis catheters—the establishment of a new experimental extracorporeal circulation system using pig veins

Suguru Yamamoto

Renal Replacement Therapy 2018年

ヘキサデキル基固定セルロースビーズによる蛋白結合尿毒症物質の吸着効果

山本卓, 佐藤茉美, 佐藤容子, 若松拓也, 高橋良光, 井口昭, 大森健太郎, 鈴木靖, 惠以盛, 金子佳賢, 後藤眞, 風間順一郎, 下條文武, 成田一衛

日本透析医会雑誌 32 ( 3 ) 516 - 519 2017年12月

Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency 査読

Akira Iguchi, Suguru Yamamoto, Mihoko Yamazaki, Kazuyuki Tasaki, Yasushi Suzuki, Junichiro James Kazama, Ichiei Narita

Clinical and Experimental Nephrology 22 ( 4 ) 1 - 8 2017年11月

原因不明の低Na血症および急性肺水腫に対してCHDFが奏功した一例

村竹佑太, 黒澤陽一, 若松拓也, 細島康宏, 保坂聖子, 山本卓, 後藤眞, 成田一衛

新潟急性血液浄化研究会抄録集 4回 6 - 7 2017年11月

Prevalence of Earlobe Creases and Their Association With History of Cardiovascular Disease in Patients Undergoing Hemodialysis: A Cross-Sectional Study 査読

Minako Wakasugi, Junichiro James Kazama, Kazuko Kawamura, Suguru Yamamoto, Masaaki Nagai, Kentaro Omori, Saori Yokota, Hirokazu Fujikawa, Ikuo Aoike, Tsukasa Omori, Ichiei Narita

Therapeutic Apheresis and Dialysis 21 ( 5 ) 478 - 484 2017年10月

Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders 査読

Hirotaka Komaba, Mia Wang, Masatomo Taniguchi, Suguru Yamamoto, Takanobu Nomura, Douglas E. Schaubel, Abigail R. Smith, Jarcy Zee, Angelo Karaboyas, Brian Bieber, Masafumi Fukagawa, Francesca Tentori

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 12 ( 9 ) 1489 - 1497 2017年9月

ボルテゾミブが奏功した意義不明の単クローン性ガンマグロブリン血症(MGUS)に伴う重鎖沈着症(HCDD)の一例

須藤真則, 若松拓也, 石川友美, 羽深将人, 細島康宏, 山本卓, 伊藤由美, 今井直史, 金子佳賢, 瀧澤淳, 成田一衛

日本腎臓学会誌 59 ( 6 ) 869 - 869 2017年9月

Potential Benefit Associated With Delaying Initiation of Hemodialysis in a Japanese Cohort. 査読国際誌

Higuchi S, Nakaya I, Yoshikawa K, Chikamatsu Y, Sada KE, Yamamoto S, Takahashi S, Sasaki H, Soma J

Kidney international reports 2 ( 4 ) 594 - 602 2017年7月

Prolactin Upregulates Female-Predominant P450 Gene Expressions and Downregulates Male-Predominant Gene Expressions in Mouse Liver 査読

Yuya Sato, Yoshikatsu Kaneko, Takamasa Cho, Kei Goto, Tadashi Otsuka, Suguru Yamamoto, Shin Goto, Hiroki Maruyama, Ichiei Narita

DRUG METABOLISM AND DISPOSITION 45 ( 6 ) 586 - 592 2017年6月

Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients 査読

Hirofumi Watanabe, Shin Goto, Daisuke Kondo, Takuma Takata, Hajime Yamazaki, Michihiro Hosojima, Suguru Yamamoto, Yoshikatsu Kaneko, Ryuji Aoyagi, Ichiei Narita

CLINICAL AND EXPERIMENTAL NEPHROLOGY 21 ( 2 ) 257 - 265 2017年4月

インドキシル硫酸はマクロファージのAhR/NF-κB/MAPK系を活性化させる一方、NLRP3インフラマソーム活性を抑制する

若松拓也, 山本卓, 松尾浩司, 金子佳賢, 後藤眞, 風間順一郎, 成田一衛

日本腎臓学会誌 59 ( 3 ) 283 - 283 2017年4月

レニン-アンギオテンシン系阻害は腎不全ラットの破骨細胞活性を抑制し、石灰化障害を改善させる

佐藤容子, 若松拓也, 山本卓, 伊藤明美, 岩崎香子, 金子佳賢, 後藤眞, 深川雅史, 風間順一郎, 成田一衛

日本腎臓学会誌 59 ( 3 ) 276 - 276 2017年4月

Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis 査読

Suguru Yamamoto

IJC Metabolic & Endocrine 13 6 - 11 2016年12月

透析非導入に至った超高齢者慢性腎臓病患者の1例

山本卓, 吉澤優太, 後藤慧, 高井千夏, 酒巻裕一, 金子佳賢, 後藤眞, 風間順一郎, 丸山弘樹, 成田一衛

日本老年医学会雑誌 53 ( 4 ) 447 - 448 2016年10月

[Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis]. 査読

Yamamoto S, Ei I, Narita I

Clinical calcium 26 ( 9 ) 1301 - 1307 2016年9月

Extracapillary proliferation and arteriolar hyalinosis are associated with long-term kidney survival in IgA nephropathy 査読

Yoshikatsu Kaneko, Kazuhiro Yoshita, Emiko Kono, Yumi Ito, Naofumi Imai, Suguru Yamamoto, Shin Goto, Ichiei Narita

CLINICAL AND EXPERIMENTAL NEPHROLOGY 20 ( 4 ) 569 - 577 2016年8月

治療中に播種性水痘感染を発症したループス腎炎の2例

羽深将人, 永野敦嗣, 細島康宏, 山本卓, 中枝武司, 和田庸子, 風間順一郎, 成田一衛

日本腎臓学会誌 58 ( 6 ) 779 - 779 2016年8月

血液透析導入後に腎生検を施行しIgA腎症と診断した一例

熊木隆之, 石川友美, 羽深将人, 細島康宏, 山本卓, 今井直史, 伊藤由美, 風間順一郎, 成田一衛

日本透析医学会雑誌 49 ( Suppl.1 ) 583 - 583 2016年5月

ヘキサデシル基固定セルロースビーズは蛋白結合尿毒症物質を吸着する

山本卓, 風間順一郎, 佐藤茉美, 若松拓也, 高橋良光, 惠以盛, 大森健太郎, 井口昭, 鈴木靖, 成田一衛

日本透析医学会雑誌 49 ( Suppl.1 ) 530 - 530 2016年5月

レニン-アンギオテンシン系阻害は腎不全ラットの骨石灰化と弾性を改善させる

若松拓也, 山本卓, 松尾浩司, 岩崎香子, 伊藤明美, 風間順一郎, 成田一衛

日本腎臓学会誌 58 ( 3 ) 293 - 293 2016年5月

Leptin deficiency down-regulates IL-23 production in glomerular podocytes resulting in an attenuated immune response in nephrotoxic serum nephritis 査読

Kei Goto, Yoshikatsu Kaneko, Yuya Sato, Tadashi Otsuka, Suguru Yamamoto, Shin Goto, Keiko Yamamoto, Tadashi Yamamoto, Hiroshi Kawachi, Michael P. Madaio, Ichiei Narita

INTERNATIONAL IMMUNOLOGY 28 ( 4 ) 197 - 208 2016年4月

Is IgA nephropathy (IgAN) a familial or sporadic disease? 査読

Ichiei Narita, Yoshikatsu Kaneko, Yumi Itoh, Yuichi Sakamaki, Seitaro Iguchi, Suguru Yamamoto, Minako Wakasugi, Junichiro J. Kazama, Shin Goto

Pathogenesis and Treatment in IgA Nephropathy: An International Comparison 43 - 51 2016年3月

Removal of uremic toxins by renal replacement therapies: a review of current progress and future perspectives

Suguru Yamamoto

Renal Replacement Therapy 2016年

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy 査読

Ryo Koda, Junichiro James Kazama, Koji Matsuo, Kazuko Kawamura, Suguru Yamamoto, Minako Wakasugi, Tetsuro Takeda, Ichiei Narita

CLINICAL AND EXPERIMENTAL NEPHROLOGY 19 ( 4 ) 710 - 717 2015年8月

生体腎移植2例が長期生着中の家族性巣状分節性糸球体硬化症の1家系

坪野俊介, 酒巻裕一, 山本卓, 今井直史, 伊藤由美, 田崎正行, 中川由紀, 齋藤和英, 後藤眞, 高橋公太, 成田一衛

日本腎臓学会誌 57 ( 6 ) 947 - 947 2015年8月

TAFRO症候群に合併した急性腎障害に対してCRRTを要した1例

須藤真則, 酒巻裕一, 若松彩子, 渡辺博文, 蒲澤秀門, 山本卓, 金子佳賢, 山崎肇, 風間順一郎, 成田一衛

日本腎臓学会誌 57 ( 6 ) 951 - 951 2015年8月

Advanced Thymic Cancer Treated with Carboplatin and Paclitaxel in a Patient Undergoing Hemodialysis 査読

Satoru Miura, Hiroshi Kagamu, Takehito Sakai, Koichiro Nozaki, Katsuaki Asakawa, Hiroshi Moro, Masaaki Okajima, Satoshi Watanabe, Suguru Yamamoto, Noriaki Iino, Shin Goto, Junichiro James Kazama, Hirohisa Yoshizawa, Ichiei Narita

INTERNAL MEDICINE 54 ( 1 ) 55 - 58 2015年

Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency 査読

Akira Iguchi, Junichiro J. Kazama, Suguru Yamamoto, Kazuhiro Yoshita, Yasuo Watanabe, Noriaki Iino, Ichiei Narita

NEPHRON 131 ( 3 ) 161 - 166 2015年

ブタ静脈血管を用いた短期カテーテルの評価システムの開発に関する検討

髙橋良光, 風間順一郎, 山本卓, 成田一衛, 追手巍

日本透析医学会雑誌 48 ( 6 ) 393 - 394 2015年

経皮的腎動脈形成術により腎機能の著明な改善が得られた片側腎動脈狭窄の一例

大塚忠司, 酒巻裕一, 山本卓, 金子佳賢, 伊藤由美, 今井直史, 成田一衛, 猪俣繁, 捧博輝

日本腎臓学会誌 56 ( 6 ) 863 - 863 2014年8月

A hip fracture in a dialysis patient with Aβ2M amyloidosis. 査読

Kazama JJ, Yamamoto S, Wakasugi M, Narita I

Kidney international 85 ( 1 ) 214 - 215 2014年1月

肝性脳症による意識障害が血液透析濾過により改善しえたバッド・キアリ症候群合併透析患者の一例

若松拓也, 矢田雄介, 山本卓, 中枝武司, 飯野則昭, 後藤眞, 風間順一郎, 成田一衛

日本腎臓学会誌 55 ( 6 ) 1045 - 1045 2013年8月

Cause-specific excess mortality among dialysis patients: Comparison with the general population in Japan 査読

Minako Wakasugi, Junichiro James Kazama, Suguru Yamamoto, Kazuko Kawamura, Ichiei Narita

Therapeutic Apheresis and Dialysis 17 ( 3 ) 298 - 304 2013年6月

腹膜透析患者におけるESA切替用量の検討、新潟県内多施設共同研究

飯野則昭, 川村和子, 山本卓, 後藤眞, 丸山弘樹, 風間順一郎, 成田一衛

日本透析医学会雑誌 46 ( Suppl.1 ) 913 - 913 2013年5月

血液透析患者に合併した進行期胸腺癌に対し全身化学療法を施行した1例

片桐隆幸, 三浦理, 山崎美穂子, 山本卓, 坂井勇仁, 飯野則昭, 後藤眞, 各務博, 風間順一郎, 成田一衛

日本透析医学会雑誌 46 ( Suppl.1 ) 547 - 547 2013年5月

新潟県における腹膜透析医療の実際

飯野則昭, 山本卓, 川村和子, 後藤眞, 風間順一郎, 丸山弘樹, 成田一衛

日本透析医学会雑誌 46 ( Suppl.1 ) 769 - 769 2013年5月

A combination of healthy lifestyle factors is associated with a decreased incidence of chronic kidney disease: A population-based cohort study 査読

Minako Wakasugi, Junichiro J. Kazama, Suguru Yamamoto, Kazuko Kawamura, Ichiei Narita

Hypertension Research 36 ( 4 ) 328 - 333 2013年4月

[Kidney and bone update : the 5-year history and future of CKD-MBD. Treatment for dialysis-related amyloidosis update]. 査読

Yamamoto S, Kazama JJ, Narita I

Clinical calcium 22 ( 7 ) 1089 - 1098 2012年7月

High Mortality Rate of Infectious Diseases in Dialysis Patients: A Comparison With the General Population in Japan 査読

Minako Wakasugi, Kazuko Kawamura, Suguru Yamamoto, Junichiro James Kazama, Ichiei Narita

THERAPEUTIC APHERESIS AND DIALYSIS 16 ( 3 ) 226 - 231 2012年6月

Hypogammaglobulinemic Patient with Polyarthritis Mimicking Rheumatoid Arthritis Finally Diagnosed as Septic Arthritis Caused by Mycoplasma hominis 査読

Hiroe Sato, Noriaki Iino, Riuko Ohashi, Takako Saeki, Tomoyuki Ito, Maki Saito, Yutaka Tsubata, Suguru Yamamoto, Shuichi Murakami, Takeshi Kuroda, Yoshinari Tanabe, Junichi Fujisawa, Takehiro Murai, Masaaki Nakano, Ichiei Narita, Fumitake Gejyo

INTERNAL MEDICINE 51 ( 4 ) 425 - 429 2012年

Nuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases 査読

Junichiro James Kazama, Suguru Yamamoto, Ichiei Narita, Satoshi Kurihara

THERAPEUTIC APHERESIS AND DIALYSIS 15 9 - 13 2011年6月

Cancellous Bone Volume Is an Indicator for Trabecular Bone Connectivity in Dialysis Patients 査読

Junichiro James Kazama, Ryo Koda, Suguru Yamamoto, Ichiei Narita, Fumitake Gejyo, Akihide Tokumoto

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 5 ( 2 ) 292 - 298 2010年2月

Comparison of Quantitative Cancellous Bone Connectivity Analyses at Two- and Three-Dimensional Levels in Dialysis Patients 査読

Junichiro James Kazama, Ryo Koda, Suguru Yamamoto, Ichiei Narita, Fumitake Gejyo, Akihide Tokumoto

CALCIFIED TISSUE INTERNATIONAL 84 ( 1 ) 38 - 44 2009年1月

The Risk of Gallbladder Stone Formation Is Increased in Patients with Predialysis Chronic Kidney Disease but Not Those Undergoing Chronic Hemodialysis Therapy 査読

Suguru Yamamoto

Nephron Clinical Practice 111 ( 3 ) c167 - 72 2009年

The Risk of Gallbladder Stone Formation Is Increased in Patients with Predialysis Chronic Kidney Disease but Not Those Undergoing Chronic Hemodialysis Therapy 査読

Junichiro James Kazama, Sakumi Kazama, Ryo Koda, Suguru Yamamoto, Ichiei Narita, Fumitake Gejyo

NEPHRON CLINICAL PRACTICE 111 ( 3 ) C167 - C172 2009年

Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism 査読

Kiyoko Hosaka, Junichiro James Kazama, Suguru Yamamoto, Yumi Ito, Noriaki Iino, Hiroki Maruyama, Akihiko Saito, Ichiei Narita, Fumitake Gejyo

JOURNAL OF BONE AND MINERAL METABOLISM 26 ( 2 ) 185 - 190 2008年3月

[Mechanism of beta(2)-microglobulin-related amyloid fibril formation in CKD]. 査読

Yamamoto S, Kazama JJ

Clinical calcium 17 ( 5 ) 740 - 744 2007年5月

Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism 査読

JJ Kazama, K Omori, S Yamamoto, Y Ito, H Maruyama, Narita, I, F Gejyo, Y Iwasaki, M Fukagawa

THERAPEUTIC APHERESIS AND DIALYSIS 10 ( 3 ) 262 - 266 2006年6月

A beta-2M-amyloidosis and related bone diseases 査読

JJ Kazama, S Yamamoto, N Takahashi, Y Ito, H Maruyama, Narita, I, F Gejyo

JOURNAL OF BONE AND MINERAL METABOLISM 24 ( 2 ) 182 - 184 2006年3月

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism 査読

Yuko Oyama, Junichiro James Kazama, Kentaro Omori, Noboru Higuchi, Shigemi Kameda, Suguru Yamamoto, Yumi Ito, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo

Clinical and Experimental Nephrology 9 ( 2 ) 142 - 147 2005年6月

Molecular interactions in the formation and deposition of beta(2)-microglobuhn-related amyloid fibrils 査読

H Naiki, S Yamamoto, K Hasegawa, Yamaguchi, I, Y Goto, F Gejyo

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS 12 ( 1 ) 15 - 25 2005年3月

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients 査読

JJ Kazama, F Sato, K Omori, H Hama, S Yamamoto, H Maruyama, Narita, I, F Gejyo, T Yamashita, S Fukumoto, M Fukagawa

KIDNEY INTERNATIONAL 67 ( 3 ) 1120 - 1125 2005年3月

Direct comparison between two 1-84PTH assays in dialysis patients. 査読

Kazama JJ, Yamamoto S, Kameda S, Maruyama H, Narita I, Shigematsu T, Gejyo F

Nephron. Clinical practice 99 ( 1 ) c8 - 12 2005年

Direct comparison between two 1-84PTH assays in dialysis patients 査読

JJ Kazama, S Yamamoto, S Kameda, H Maruyama, Narita, I, T Shigematsu, F Gejyo

NEPHRON CLINICAL PRACTICE 99 ( 1 ) C8 - C12 2005年

Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta(2)-microglobulin amyloid fibrils in vitro 査読

Yamaguchi, I, H Suda, N Tsuzuike, K Seto, M Seki, Y Yamaguchi, K Hasegawa, N Takahashi, S Yamamoto, F Gejyo, H Naiki

KIDNEY INTERNATIONAL 64 ( 3 ) 1080 - 1088 2003年9月

Successful perioperative blood purification therapy in patients with maintenance hemodialysis therapy who underwent living donor liver transplantation 査読

JJ Kazama, N Takahashi, Y Ito, Y Watanabe, N Iino, S Iguchi, A Oyanagi, H Obayashi, S Ito, H Maruyama, Narita, I, S Yamamoto, Y Sato, A Tsuchiya, T Ichida, F Gejyo

CLINICAL NEPHROLOGY 59 ( 3 ) 229 - 233 2003年3月

Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation

K Inai, Y Wano, S Yamamoto, Y Ikebata, H Iwasaki, H Tsutani, H Naiki, T Ueda

ANTICANCER RESEARCH 19 ( 6C ) 5631 - 5634 1999年11月

　前のページ - 次のページ　

<山本 卓>

論文 - 山本 卓

<山本　卓>

論文 - 山本　卓